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Background: New Zealand has an aging population with increasing demand for long-
term aged care residential facilities. Irritable bowel syndrome (IBS) is a common 
functional gastrointestinal (GI) symptoms affecting 10 – 15% of the Western 
population. Restriction of a group of fermentable carbohydrates (FODMAPs) has been 
shown to significantly improve GI symptoms in patients with IBS. Currently there are 
no New Zealand data on the frequency and nature of GI symptoms and FODMAP 
intake of long-term aged care residents.   
Objectives: The overarching aim of this study is to assess the number of residents in 
a residential care facility who are suffering from IBS-like symptoms, particularly 
residents with diarrhoea or incontinence and to understand whether FODMAP intake 
is associated with IBS symptoms. Specific objectives are as follows:  
- To describe the frequency of GI symptoms in rest home (RH), hospital level 
care (H) and free-living (FL) residents of  a retirement village. 
- To determine the nature and quantity of commonly consumed high FODMAP 
foods by RH and H residents.  
- To assess individual FODMAP intake of RH and H residents. 
- To investigate any associations between FODMAP intake and IBS symptoms in 
RH and H residents.   
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Design: One hundred and sixteen eligible RH and H residents and 133 eligible FL, or 
independent residents living in a retirement village were invited to take part in the 
study. The Gastrointestinal Symptom Rating Score questionnaire modified for 
patients with IBS (GSRS-IBS) with six additional questions looking at upper GI 
symptoms was used and differences in responses between gender and level of care 
were compared. Dietary FODMAP intake was assessed for 30 RH or H residents with 
highest total GSRS-IBS score (symptomatic group) and 30 age, sex, and level of care 
matched asymptomatic residents with low total GSRS-IBS score. Comparisons were 
made between symptomatic and asymptomatic groups for macronutrient, 
micronutrient and FODMAP intakes. A simple regression analysis was conducted to 
determine the relationship between total FODMAP intake and GSRS-IBS score.   
Results: 74 (64%) RH and H residents and 51 (38%) FL residents completed the GI 
symptom questionnaire. Just over half of RH and H residents reported perceived 
discomfort of bloating-related and upper GI-related symptoms while most common 
symptoms reported by FL residents were diarrhoea-related (59%) and bloating-related 
(57%) discomforts. However, no significant differences were observed by gender or 
level of care for individual or total GI symptom scores. Dietary analysis was 
completed in 27 symptomatic and 27 asymptomatic RH and H residents who had all 
three main meals at the facility during data collection. A large quantity of lactose 
(16g/d consumed on average) from milk and milk products contributed to the total 
FODMAP intake. Wheat-based products, dried fruit, and homemade soups 
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(containing onion, other high FODMAP vegetables and flour) contributed to high 
oligosaccharide intake, prunes, canned fruit, mushroom, onion and corn contributed 
to high polyol intake and fruit salad, orange juice and apple based dishes contributed 
towards fructose in excess of glucose intake. There were no significant differences in 
nutrient intake between the symptomatic and asymptomatic groups and there was no 
significant relationship between FODMAP intake and total GSRS-IBS score.  
Conclusion: This novel study has produced data on GI symptoms and FODMAP 
intake in older adults living in a retirement village in New Zealand. A larger study 
with a bigger sample size and residents from multiple facilities across New Zealand 
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Consistent with other developed countries, the New Zealand population is aging with 
15% (698,400 people) of the population aged over 65 years, an increase of 3.6 % 
between 2015 and 2016.2 This phenomenon is partly due to the rising life expectancy 
resulting from factors such as advances in medical technology and sanitation. In New 
Zealand, the life expectancy at birth has increased from 76.3 years (male) and 81.1 
years (female) in 2001 to 79.5 and 83.2 years for male and female respectively in 2013.3 
Such population growth has a huge impact on the cost of health as well as disability 
services, particularly the demand for long-term care facilities.4  Furthermore, a study 
conducted in Auckland-based residential care facilities has shown reduction in 
“independent residents” while the trend shows an increase in “highly dependent” 
residents for functions such as continence, mobility and self-care.5  
Aging is also associated with physiological changes including changes in the 
gastrointestinal (GI) tract6,7 with increased prevalence of GI disorders8,9 which in turn 
can affect nutritional status of older adults.10 Irritable bowel syndrome (IBS) is a 
chronic disorder, characterised by abdominal discomfort or pain with altered bowel 
habits. While there is no associated mortality,11 there is a significantly impaired quality 
of life.12,13 The prevalence of IBS is estimated to be 10 – 15% in Western populations 
and is more common in women.14 Irritable bowel syndrome affects more commonly 
the younger people aged 20 and 30 years15 and prevalence is 25% lower in people aged 
over 50 years compared to younger adults.16 Few studies have assessed the prevalence 
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of IBS in the elderly, however, it is believed that as high as 22% of older people may 
have symptoms suggestive of IBS.17 Many people with IBS will significantly restrict 
food intake in an attempt to control their symptoms18 which, in combination with 
reduced oral intake often seen in aging, may lead to nutritional inadequacy.10  
Irritable bowel symptoms, in particular diarrhoea and faecal incontinence, can be both 
psychologically and socially debilitating and have a huge impact on frail elderly 
people. For instance, long-term faecal incontinence was found to be associated with 
increased mortality in long-term aged care residents,19 as faecal incontinance is one of 
many factors associated with frailty in older adults.20 Therefore, it is vital that effective 
treatment is available to improve quality of life in affected elderly people as well as 
reducing healthcare costs associated with faecal incontinence and diarrhoea.   
The low FODMAP (Fermentable Oligosaccharides, Disaccharides, Monosaccharides 
and Polyols) diet has been shown to significantly improve functional gut symptoms 
in adults with IBS.21-23 However, the FODMAPs composition of the diet of older people 
nor the efficacy of the low FODMAP diet in elderly have been studied previously.    
Therefore, the goal of this thesis is to assess the GI symptoms and intakes of 
FODMAPs in the older adults living in a retirement village and to investigate the 
relationship between these two variables. The overarching aim and the objectives are 




2. Literature review 
 
This section has been adapted from our publication, “Efficacy of the low FODMAP 
diet for treating irritable bowel syndrome: the evidence to date” (Clinical and 
Experimental Gastroenterology, 2016 Jun 17;9:131-42, Appendix A).  The publication 
provides background to the FODMAP diet as a treatment of IBS.  
 
2.1 Efficacy of the low FODMAP diet for treating irritable bowel syndrome: 
the evidence to date 
 
2.1.1 What is Irritable Bowel Syndrome? 
 
Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder characterized 
by symptoms of abdominal pain, bloating, and altered bowel habit such as 
constipation, diarrhea or both.24 It is the most common GI condition seen by general 
practitioners11 and accounts for up to 50% of patients seen in gastroenterology clinics.25 
IBS is a clinical diagnosis and is made using symptom-based criteria such as Rome III 
criteria26 (the current gold standard for IBS diagnosis [Table 1]) in addition to the 
exclusion of any organic disease.27 Although the exact cause of IBS is unknown, there 
are increasing insights concerning the possible etiology and pathophysiology of IBS. 
These include heightened pain sensitivity or visceral hypersensitivity,28,29 abnormal 
gut motility,30 small intestinal bacterial overgrowth,31 low-grade intestinal 
inflammation,32 psychosocial factors,33 and dysregulated gut-brain axis.34,35 Thus, IBS 
appears to be a multifactorial, albeit incompletely understood, disorder.  
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The global IBS prevalence is 10 – 20% depending on the diagnostic criteria used and 
the geographic region.16 The varying prevalence of IBS among countries may be due 
to variable application of the diagnostic criteria, demographic differences, and other 
factors such as health care utilization, health beliefs or diet.16,36 IBS is also more 
common in women than in men and in individuals below the age of 50 years.16 IBS can 
be sub-classified into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), mixed 
IBS (IBS-M), or unsubtyped (IBS-U) based on their predominant bowel pattern.26 IBS 
is associated with high health care costs37,38 as well as impaired quality of life (QoL), 
compared to the general population.39-41 The QoL also compares poorly with other 
chronic conditions such as gastroesophageal reflux disease, diabetes mellitus and end-
stage renal disease.39  
Table 1. Rome III diagnostic criteria for irritable bowel syndrome26 
 
 
The main treatment goal for clinicians treating patients with IBS is to alleviate global 
GI symptoms; however, because of the multiple symptoms described by patients with 
IBS, this is often challenging. While an effective physician-patient relationship is 
considered the cornerstone for effective treatment,42 a combination of pharmaceutical 
Recurrent abdominal pain or discomforta at least 3 days per month in the 
last 3 monthsb associated with two or more of the following:  
1. Improvement with defecation  
2. Onset associated with a change in frequency of stool  
3. Onset associated with a change in form (appearance) of stool 
Notes: aDiscomfort is an uncomfortable sensation not described as pain. 
bCriteria fulfilled for the last 3 months with symptom onset at least 6 
months prior to diagnosis. 
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and non-pharmaceutical approaches are now considered. However, the traditional 
pharmacological treatments such as bulking agents, anticholinergics, antispasmodics, 
and antidiarrheals often do not provide adequate symptomatic relief in patients with 
IBS if used alone.43,44 A more holistic approach using nonpharmacological therapies 
such as dietary manipulation, exercise, cognitive-behavioral therapy, and 
hypnotherapy seems to provide further benefits in these patients.45 The “Diet as a 
therapy for IBS” section discuses some of the dietary manipulations aimed at 
improving the global symptoms of IBS.   
2.1.2 Diet as a therapy for IBS 
 
Nearly two-thirds of patients with IBS perceive their GI symptoms to be food-
related.46 Incompletely absorbed carbohydrates (found in foods such as lactose found 
in dairy products, beans, onion, cabbage, apples, and wheat) as well as fatty foods, 
coffee, alcohol, and spicy foods have all been found to trigger or aggravate GI 
symptoms.46,47  
Many early studies focused on strict exclusion or elimination diets followed by food 
rechallenge to investigate the role of food intolerance in patients with IBS. For example, 
25 consecutive patients diagnosed with IBS-D were asked to limit their diets to a single 
meat, a single fruit, and distilled or spring water for 1 week.48 Fourteen patients (67%) 
of those who completed the diet were symptom free.48  Six out of 14 patients then 
underwent a randomized double-blind food challenge in which participants were fed 
a liquidized preparation of either a test food (believed to provoke symptoms) or a 
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control food via a nasogastric tube, and food intolerance was confirmed.48 McKee and 
colleagues49 repeated the dietary limitation component of this study including other 
subtypes of IBS and found that only 6/40 (15%) patients with IBS had symptomatic 
improvement (mostly in IBS-D). In another study, nearly half (91/189) of a cohort of 
female patients with IBS experienced symptomatic improvement after 3 weeks of a 
strict exclusion diet without dairy products, cereals, citrus fruits, potatoes, tea, coffee, 
alcohol, additives, and preservatives, while the remainder (98/189) found no 
improvement.50 Parker and colleagues51 described a similar but nutritionally adequate 
exclusion diet where alternative foods to those that were being excluded were 
suggested to participants. However, only 39 of 96 (41%) patients with IBS who 
completed the 2-week exclusion diet improved.51 The variability in responses to these 
exclusion diets is likely due to differences in study protocols including duration of 
exclusion diet, the types of foods excluded, as well as the subtypes of IBS participants 
recruited in the study. Well-designed randomized controlled trials have been lacking 
when it comes to the investigation of many such exclusion diets. However, designing 
controlled dietary intervention studies is difficult, particularly with regard to blinding 
study participants. Given that placebo response rates in IBS trials may be as high as 
40%,52 difficulties in blinding can be a significant source of bias. 
Lactose malabsorption resulting from lactase deficiency is known to cause abdominal 
pain, flatulence, and loose bowel motions. Hypolactasia or lactase deficiency is 
generally due to primary or secondary deficiency as congenital lactase deficiency at 
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birth is extremely rare.53 Approximately 70% of the world population have primary 
lactose deficiency resulting from loss of lactase activity, which begins between the 
ages of 2 and 6 years,54 whereas secondary lactase deficiency often occurs as a result 
of GI illness such as viral gastroenteritis or celiac disease.53 Some studies have 
investigated the role of low lactose diet in the management of IBS with mixed results. 
In one study, 27% of 122 patients with IBS were found to have lactose malabsorption 
with positive lactose hydrogen breath test; however, only nine (39%) had 
improvement in their symptoms following the low lactose diet.55  In contrast, Böhmer 
et al56 found a marked reduction in symptoms with a lactose-restricted diet in patients 
with IBS with lactose malabsorption (24%) diagnosed with a hydrogen breath test, but 
no improvement in patients with IBS who tested negative for lactose malabsorption. 
Therefore, although conflicting, the results concerning lactose malabsorption and 
restriction suggest that lactose restriction should be tried in patients with IBS in whom 
lactose malabsorption is proven but that other dietary restrictions may also be 
required.  
Probiotics, a food supplement of a single live microbe or mix of microbes with 
beneficial properties, is another dietary treatment that has been studied extensively in 
both IBS and also many other conditions. A systematic review and meta-analysis of 
14 randomized control trials of probiotics in patients with IBS found a modest 
improvement in overall symptoms with probiotic use for several weeks (odds ratio, 
1.6; 95% confidence interval, 1.2 – 2.2).57 However, given that each probiotic may have 
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different characteristics, including variable effects on cytokines, host microbiota, and 
other potential targets, it is likely that the effects will be specific to each probiotic 
rather than the entire class. 
In fibre supplementation studies, soluble fibre (psyllium)58 but not insoluble fibre 
(bran)58,59 was found to be effective in the management of patients with IBS. In fact, 
bran supplementation led to worsened symptoms in 55% of the patients.59 A small 
study of 13 overweight or obese participants with IBS-D who completed the study 
found significant improvement in their stool consistency, pain, and QoL with a very 
low-carbohydrate diet (20 g carbohydrates/d);60 however, larger studies including 
patients with normal body mass index are needed to confirm these results.   
A double-blind, randomized, placebo-controlled rechallenge trial of gluten in patients 
with IBS resulted in significantly worse overall symptoms of pain, bloating and stool 
consistency in the gluten group (who received gluten-containing foods) compared to 
the placebo group.61 Interestingly, a subsequent double-blinded cross-over trial in 
subjects with non-celiac gluten sensitivity (NCGS) and IBS without celiac disease 
performed by the same group found no evidence of specific or dose-dependent effects 
of gluten, while improvements in symptoms were seen with a diet low in fermentable 
carbohydrates (Fermentable Oligosaccharide, Disaccharide, Monosaccharide, and 
Polyols [FODMAPs]).62 This study62 suggests that the carbohydrate component 
(fructans and galacto-oligosaccharides) of the wheat as opposed to the gluten may be 
responsible for the IBS symptoms experienced by patients with NCGS and IBS. Thus, 
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it may be that a combination of incompletely absorbed carbohydrates may be 
responsible for eliciting many symptoms of IBS rather than one specific food or food 
component.  
2.1.3 The low FODMAP diet 
 
FODMAPs are a group of carbohydrates that are poorly absorbed in the small intestine 
and subsequently fermented in the small or large intestine.63 These poorly absorbed 
short-chain carbohydrates include fructose and lactose (in patients who malabsorb 
these with impaired enzyme activity or transport mechanisms), fructans, galacto-
oligosaccharides and polyols or sugar alcohols. Table 2 lists representative examples 
of common foods that are known to be high in FODMAPs and examples of suitable 
low FODMAP alternatives. The implementation of low FODMAP diet is beyond the 
scope of this paper, but is covered in detail elsewhere.64,65 
2.1.4 How does a low FODMAP diet work in IBS? 
 
Not all FODMAPs exacerbate abdominal symptoms in patients with IBS. The presence 
and degree of abdominal symptoms in a given individual depends on the degree of 
malabsorption experienced by the individual. There are two main mechanisms 
responsible for the induction of symptoms in patients with IBS by FODMAPs. First, 
FODMAPs are poorly absorbed by the small intestine and are osmotically active, 
leading to net secretion of fluid into the small intestine. This may distend the small 
intestine, leading to abdominal symptoms, in addition to increasing water delivered 
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to the colon. In a study of ileostomates,66 intestinal output was increased by 22% with 
high consumption of FODMAPs within meals secondary to an increased osmotic load. 
Table 2. Examples of food high in FODMAPs and suitable low FODMAP alternatives 














Grains: wheat-, rye-, and barley-based 
products  
Vegetables: onion, garlic, artichoke, 
leeks, beetroot, and savoy cabbage 
Fruits: watermelon, peaches, 
persimmon, prunes, nectarines and 
most dried fruit 
GOS 
Legumes: red kidney beans, baked 
beans, and soya beans 
Vegetables: beetroot and peas 
Fruit: banana, most berries 
(except boysenberries and 
blackberries), grapes, lemon, 
lime, mandarin, orange, kiwi 
fruit, pineapple, passion fruit, 
and rhubarb 
Vegetables: capsicum, bok choy, 
green beans, parsnip, silverbeet, 
cucumber, carrots, celery, 
eggplant, lettuce, potatoes, yams, 
tomatoes, and zucchini 
Grains: wheat-free grains/flour, 
gluten-free bread or cereal 
products, and quinoa 
 
Disaccharides Lactose 
Dairy products: cows/goat milk, and 
yoghurt 
Dairy products: lactose-free, 
almond or rice-based milk, 
yoghurt and ice-cream, hard 
cheese, feta and cottage cheese  
 
Monosaccharides Fructose (in excess of glucose) 
Fruits: apples, pears, watermelon, 
mango, cherries, boysenberries and 
fruit juice from high-fructose food 
Honey 
Sweeteners: high-fructose corn syrup 
fructose 
Vegetable: asparagus and snap peas 
Fruit: banana, grapes, 
honeydew, melon, kiwifruit, 
lemon, lime, mandarin, orange, 
passionfruit, paw paw, and most 
berries (except boysenberries 
and blackberries) 




Fruit: apples, pears, avocado, apricots, 
blackberries, nectarines, peaches, 
plums, prunes, and watermelon 
Mannitol 
Vegetables: sweet potato, mushrooms, 
cauliflower, and snow peas 
Sweeteners: maple syrup, and 
sugar (sucrose) 
Fruits: banana, grapes, 
honeydew, melon, kiwifruit, 
lemon, mandarin, orange, 
passionfruit, and paw paw 
Notes: Data from Monash University. Low FODMAP Diet Application. Available at: 
http://www.med.monash.edu/cecs/gastro/fodmap/. Android version accessed August 26, 
2015.90 
Abbreviations: FODMAP, fermentable oligosaccharide, disaccharide, monosaccharide, and 
polyols; FOS, fructo-oligosaccharides; GOS, galacto-oligosaccharides.  
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In addition, a recent magnetic resonance imaging study has shown an abnormal 
accumulation of fluid in the small intestine of patients with IBS following ingestion of 
an unabsorbed carbohydrate, lactulose, as well as provoking significantly more 
symptoms compared to healthy controls.67 These results support the underlying 
mechanism leading to diarrhea experienced by some patients with IBS. Second, 
FODMAPs are rapidly fermented by the colonic microbiota, leading to colonic 
distention from gas production, with associated pain and bloating. A reduction in 
breath hydrogen production, which measures the degree of gas produced by the 
microbiota, in both healthy and IBS subjects with a low FODMAP diet has been shown 
in a recent study, suggesting reduced fermentation and gas production with 
restriction of poorly absorbed carbohydrates.68 Subsequently, there was an 
improvement of GI symptoms in the patients with IBS on a low FODMAP diet.68 Thus, 
the study supports the hypothesis that rapid fermentation of undigested, unabsorbed 
FODMAPs in the colon results in distension of the large bowel, bloating and 
abdominal pain from excess gas production.  
2.1.5 Clinical studies of low FODMAP diet and IBS 
 
Studies on the effect of dietary restriction of FODMAPs in patients with IBS have 
shown consistent results supporting the efficacy of the low FODMAP diet in 
improving overall GI symptoms of adult patients with IBS (Tables 3 and 4).  However, 
as noted earlier, designing and implementing a prospective placebo-controlled 
dietary intervention study are extremely difficult. In the field of a low FODMAP diet 
17 
 
in the treatment of IBS symptoms, many studies are retrospective69,70 or prospective 
and uncontrolled,21,68-73 making the studies potentially subject to bias and confounding. 
To date, there have been two controlled trials22,70 and six randomized controlled 
trials23,68,74-77 evaluating low FODMAP diet in patients with IBS. These studies were 
conducted in Australia (four), Norway (two), Denmark (two), New Zealand (one), 
Switzerland (one), Sweden (one) and the UK (two).    
The majority of studies comprised a small number of participants (fewer than 
100),22,23,68,69,71,72,75,76,78 and two of the studies21,71 had poor study completion or response 
rates (< 50%). The average age of IBS participants ranged from 35 to 50 years and, as 
one might expect with an IBS cohort, a large proportion of the participants were 
female (66%-87%) in all studies.21-23,68-73,75-78 The common primary outcome measure 
was changes in GI symptoms (overall and/or individual symptoms); however, the use 
of scoring scales varied considerably, with a few studies using validated 
questionnaires.22,70,71,75 While not all studies assessed for dietary intake, the dietary 
assessment methodologies included food frequency questionnaire,70,71 food diaries68,74-
76 and another unspecified methods.73 Dietary advice on a low-FODMAP diet was 
mostly delivered by a specialized or trained dietitian, with the exception of two 
studies where a registered nurse had provided the dietary guidance.70,71 Not all studies 
provided the list of foods allowed in the low FODMAP diet; however, two studies70,71 
allowed peeled apples and pears and milk as part of the low FODMAP diet, which is 
not consistent with a low FODMAP diet as it has been described. Since the first low 
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FODMAP diets were described,69 there have been modifications to the food lists that 
have been prompted by new scientific data on food composition. However, robust 
data now exist describing the FODMAP content of commonly consumed foods (Table 
2). 
Randomized, double-blind, placebo controlled studies are considered the “gold 
standard” for an intervention study;79 however, this is almost impossible to apply in 
dietary interventions. The more recent study conducted by Halmos et al74 was a 
randomized controlled, single-blind crossover where 30 IBS and 9 healthy subjects 
consumed 21 days of low FODMAP diet or the typical Australian diet. The authors 
were able to address confounding variables by providing all intervention diets that 
were matched for all nutrients except for the FODMAP content. They found that 70% 
of IBS subjects (across all four subtypes of IBS) felt better on the low FODMAP diet, 
whereby the greatest symptom control was achieved and maintained after 7 days on 
the low FODMAP diet.  
Additional evidence supporting FODMAPs as “food triggers” was provided in a 
randomized placebo-controlled re-challenge trial in 25 patients with IBS with fructose 
malabsorption.23 In this study, a dose-dependent induction of GI symptoms was seen 
in the majority of patients with IBS following introduction of fructose (70%), fructans 
(77%), fructose and fructans mix (79%), compared to glucose (14%) in liquid forms 
following a low FODMAP diet. This study also supports cumulative and dose-
dependent effects of FODMAPs on inducing GI symptoms in patients with IBS.   
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Most patients with IBS find the diet easy to adhere to21,22 with better symptomatic 
improvement seen in those with the best adherence.21,69 A randomized controlled trial 
conducted by Pedersen et al77 found the low FODMAP diet as well as the probiotics 
had significantly improved the IBS symptom score compared to the normal diet. 
However, this study was unblinded, and all three groups had a significantly improved 
symptom score after 6 weeks of intervention and web-based self-monitoring of 
symptoms compared to the baseline.77  
Furthermore, the low FODMAP diet has provided symptomatic relief in more patients 
with IBS compared to a standard dietary advice consisting of healthy eating principles, 
alteration of insoluble and soluble fibres, and limiting sugar-free foods and foods 
containing sorbitol (86% and 49%, respectively).22 A recent single-blinded randomized 
controlled trial76 comparing the low FODMAP diet and the traditional dietary advice 
of regular meal pattern, avoiding or limiting certain foods such as fat, insoluble fibre, 
caffeine and ‘windy vegetables’ found reduced severity of symptoms in both groups, 
but no significant difference between the intervention groups. It was noted, however, 
the excess fructose intake was significantly lower in the traditional IBS diet group at 
the end of their study compared to baseline.  
Limitations of low FODMAP diet include lack of clear cutoff levels for FODMAP 
content in foods, limited country-specific data and unavailability of information on 
FODMAP content on food packages. However, research is being carried out to 
compile a comprehensive nutrient composition database for FODMAPs. Because the 
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diet is fairly complex, advice should be given by specialized dietitian trained in the 
area with appropriate resources and food intake should be monitored for nutritional 
adequacy. Compliance may be a factor; nonetheless the low FODMAP diet does not 
appear to alleviate GI symptoms of every IBS subject. Furthermore, the health effects 
of long-term low FODMAP diet are unknown. Human intestinal microbiota play a 
critical role in health and disease. Although inulin-type fructans and galacto-
oligosaccharides are FODMAPs, the ingestion of which may be associated with 
abdominal symptoms, they are also prebiotics, stimulating the growth of beneficial 
bacteria.80 Studies have shown reduced total bacterial abundance78 and reduced 
concentration of bifidobacteria75 following a low FODMAP diet, suggesting potential 
adverse health effects of the diet. Generally, the strict low FODMAP diet is not 
recommended to be followed long term. Reintroduction or rechallenge of FODMAP 
foods is recommended based on individual tolerance.81  
There are few low FODMAP dietary intervention studies conducted in children (not 
included in Tables 3 and 4). Until recently, these studies have focused on lactose 
malabsorption only.82,83 More recently, a pilot study84 and a randomized study85 have 
shown reduction in abdominal pain frequency in children between 7 and 17 years of 
age with the low FODMAP diet. The results from these studies have also suggested 
that a difference in the microbiome composition at the baseline may determine 
responders and non-responders to the low FODMAP diet. Specifically, the responders 
had bacteria with greater saccharolytic capacity (such as genera Sporobacter and 
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Subdoligranulum84 and Bacteroids, Ruminococcaceae and Faecalibacterium prausnitzii85) at 
baseline to break down sugars than those who did not respond to the diet. Hence, the 
reduction in GI symptoms in children with IBS was seen with the low FODMAP diet 
likely due to decrease in osmotic load and gas production from fermentation.   
In general, nearly all of the studies have used the Rome diagnostic criteria to select 
patients with IBS, which have resulted in predominance of female subjects mostly 
between the ages of 30 and 50 years. The design of the studies varied largely in terms 
of duration and the delivery of dietary intervention as well as symptom scoring tools 
or scales used. In all studies, however, improvements in overall GI symptoms were 
evident with those following a low FODMAP diet. Although the results are not 
consistent, significant improvements in diarrhea and constipation were seen in most 
studies. However, standardized dietary interventions and outcome measures were 
not used and are required to allow robust comparison in future studies. Finally, the 
first meta-analysis published in 201586 supports the efficacy of the diet in the treatment 







Table 3. Observational studies of low FODMAP diet in adults with IBS 
Study Study design Participants recruited 
























patients with IBS and 
fructose 
malabsorption 
Median age 50 years 
76% female 











delivered advice:  
• avoidance of 
high free fructose 
foods in excess of 
glucose, and high 
fructan foods 
• positive food 
choices 
• sample meal 
plan 
• coingestion of 
free glucose with 
fructose 
• avoiding foods 










using a -10 to 10 
scale  
48 (77%) adhered to 
the diet 
46 (74%) responded 




significantly better in 













patients with IBS 








39 - standard 
dietary advice 
(NICE guidelines) 
43 - low FODMAP 
dietary advice: 
•  suitable / 
unsuitable foods 
•  meal plans  
•  recipes adapted 













in low FODMAP 
(86%) than standard 
diet (49%) group 
Greater benefits were 
seen in low FODMAP 
group for bloating, 









was given 2 years 
before the study 
Questionnaires 
sent by mail 
 
63 patients with IBS 
without dietary 
guidance,  
70 with dietary 
guidance, and 42 
healthy controls 
Mean age 36 years 
85% female 
IBS diagnosis 




























114 patients (65%) 
completed study (35 
controls, 36 
unguided, 43 guided 
patients with IBS) 
In guided IBS 
patients, significant 
reduction in 
abdominal pain, but 
no significant 





guided patients with 
















46 patients with IBS 
Mean age 35 years 
76% female 


































17 (37%) completed 
study 
Reduced total IBS 
symptoms scores and 
significantly 
improved quality of 





diarrhea, but not 
constipation 
Dietary guidance also 
resulted in adequate 
intakes of vitamins 
and minerals  
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192 patients with IBS 
who had performed 
lactulose, fructose and 
lactose breath testing 
Mean age 45 years 
74% female 
IBS diagnosed by 
a 
gastroenterologist 









disease or bowel 
resection) 
Advice by a 




follow-up 6 weeks 
later  
•  lists of safe and 
restricted foods  
•  recipes and 
shopping guide  
•  reintroduction 







efficacy of the 
diet by e-mail 
or post 
90 patients with IBS 




reported in symptoms 
at follow-up (44% 
patients with 
improvement in 
abdominal pain, 38% 
in bloating, 38.5% in 























1,372 patients with 
FGID (212 patients 
with IBS) who 
performed fructose 
and lactose breath 
testing 



















• 1 week of diet 

















dietary habits  
237 of 312 (76%) 
patients completed 
the study 
Over 80% of patients 
attained adequate 
global symptom 
relief; 93% and 96% of 




85% adequate relief in 
patients with 
diarrhea, 96% with 













control and low 
FODMAP diet 
period (6 weeks 
each)  
19 IBS patients  
Median age 35 years 
81% female 
IBS (Rome III 
criteria) 
Excluded IBD, 















FODMAP diet:  
•  45-minute 
consultation 






All 19 patients with 
IBS completed the 
study 
Significant 
improvement in IBS 
in control period and 
following dietary 
intervention period 




improved to mild IBS 
severity) 
Significant IBS-QoL 
change during low 
FODMAP diet period 
Abbreviations: FODMAP, fermentable, oligosaccharide, disaccharide, monosaccharide and polyols; IBS, irritable bowel syndrome; FM, 
fructose malabsorption; IBD, inflammatory bowel disease; NICE, National Institute for Health and Clinical Excellence; MoBa FFQ, MoBa 
Food Frequency Questionnaire; SF-NDI, short-form nepean dyspepsia Index; QoL, quality of life; IBS-SSS, irritable bowel syndrome 
symptom scoring system; GSRS, gastrointestinal symptom rating scale; GI, gastrointestinal; FGID, functional gastrointestinal disorder; ITT, 
intention to treat; PP, per-protocol.  
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Table 4. Randomized controlled trials of low FODMAP diet in adults with IBS 
Study Study design Participants 


























26 participants with 
IBS and fructose 
malabsorption  
Median 38 years 
85% female 
Previously good GI 
symptom control 
while on low 
FODMAP diet 








































asked at the 





Symptoms induced in a 
dose dependent manner 
when drinks containing 
fructose (70%), fructans 
(77%), and a combination 
(79%) were given as 
opposed to 14% symptom 
induction in those 
receiving glucose drink 
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2 days of 
each diet 
15 healthy subjects  
Mean 23 years 
60% female 
15 subjects with IBS 
Mean 41 years 
87% female 





not pregnant and 
had no prebiotic 
supplements or 
antibiotics for >8 
weeks prior to 
the study 
No prior IBS 
education 
Provided low 



























five general GI 
symptoms 
Food diaries 
All subjects completed the 
study 
All symptoms were 
significantly worsened 
with high FODMAP diet 
in IBS patients 
Only increased flatus 
production was reported 






control trial  
4 weeks of 
either diet 
41 patients with IBS 
Mean age 35 years 
66% female 
IBS (Rome III 
criteria) 









lactation, use of 
probiotics, 
prebiotics, 
lactulose 4 weeks 
prior to study or 
changes in IBS 
meds prior 





•  low 
FODMAP 
diet (19) or 
control group 
with habitual 









Food diaries  
All 41 patients were 
included for ITT and 35 in 
the PP analysis 
At follow-up, more 
patients in the intervention 
group reported adequate 
symptom control with ITT 
(68% vs 23%) and for PP 










21 days of 
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45 participants  
33 IBS (mean age 41 
years, 70% female) 
12 healthy 
individuals (mean 
age 31 years, 75% 
female) 
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30 IBS participants (91%) 
and 8 controls (67%) 
completed the study  
70% IBS subjects had 
lower overall GI symptom 
scores on low FODMAP 
diet compared with typical 
and subjects’ habitual diet 
Similar results with 
individual symptoms 
Minimal or unaltered 
















123 patients with IBS 
Median age 37 years 
73% female 










as weight loss 
>5kg, anemia, 
fever, colorectal 





6 weeks of:  
• 42 low 
FODMAP 
diet or  
•  40 normal 
Danish/Weste
rn diet or  
















34 (81%), 37 (92%) and 37 
(90 %) completed the low 
FODMAP, normal and 
probiotic diet respectively 
A significant reduction in 
IBS-SSS in all three groups 
after 6 weeks from their 
baseline 
No significant reduction in 
IBS score in any groups for 
IBS-C type and no 
difference between normal 
diet and probiotics 
A significant reduction of 
IBS-SSS in low FODMAP  
and probiotic groups 
compared to normal diet 
IBS-QoL was statistically 









4 weeks of 
either diet 
75 patients with IBS 
Mean age 43 years 
82% female 
 
IBS (Rome III 
criteria), IBS-SSS 















disease and other 










on foods to 
avoid and 
alternatives.  



















33 (87%) low FODMAP 
and 34 (92%) traditional 
IBS diet group completed 
the study 
IBS symptom severity was 
significantly reduced in 
both groups compared to 
base line; however, the 
score did not differ 
between the groups 
19 (50%) low FODMAP 
group and 17 (46%) 
traditional IBS diet group 




Abbreviations: FODMAP, fermentable, oligosaccharide, disaccharide, monosaccharide and polyols; IBS, irritable bowel syndrome; 
CHO, carbohydrates; GI, gastrointestinal; GSRS, gastrointestinal symptom rating scale; ITT, intention to treat; PP, per-protocol; VAS, 
visual analog scale; QoL, quality of life; BMI, body mass index; IBS-SSS, irritable bowel syndrome symptom scoring system; IBS-C, 
constipation-predominant IBS; IBD, inflammatory bowel disease.  
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2.1.6 Low FODMAP diet in other diseases 
 
There are some studies in which low FODMAP diet has been applied to improve other 
lower GI disorders. For example, functional gut symptoms or IBS-type symptoms are 
common in patients with inflammatory bowel disease (IBD), with a greater prevalence 
seen in Crohn’s disease than in patients with ulcerative colitis.87 Gearry et al88 have 
demonstrated that restriction in FODMAPs improved overall abdominal symptoms 
as well as abdominal pain, bloating, wind and diarrhea in patients with IBD in a 
retrospective study. Similarly, reduction in dietary FODMAPs intake improved stool 
output and consistency in patients with ulcerative colitis following ileorectal 
anastomosis or ileal pouch formation and colectomy.89 Both of these studies have 
shown improvement with good adherence to the diet. As mentioned earlier in this 
review, significant improvements in GI symptoms were also seen in NCGS subjects 
with IBS62 and in all other types of patients with functional GI disorder.87   
2.1.7 Future directions 
 
Standardized dietary intervention in low FODMAP diet intervention studies and the 
use of validated symptom scales as predefined primary outcomes are essential to 
ensure that the results may be generalizable across larger and more diverse 
populations. Furthermore, modifications of the low FODMAP diet to individual 
tolerance should be considered in order to test the true efficacy of low FODMAP diet 
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in long-term management of IBS. Finally, the long-term effect of a low FODMAP diet 
on the colonic health, particularly the microbiome, requires further investigation.  
2.1.8 Conclusion 
 
In summary, the evidence to date indicates that restriction of FODMAPs is an effective 
dietary intervention for reducing IBS symptoms. There are now well-designed clinical 
trials to support the efficacy of low FODMAP diet with alleviation of GI symptoms in 
majority of patients with IBS. More studies are required to assess long-term efficacy 
of low FODMAP diet following food rechallenge and to ascertain any adverse 
outcomes from effects on the gut microbiota.   
2.2 Studies in New Zealand and Australia 
 
 2.2.1 Prevalence of IBS and intakes of FODMAP 
 
In New Zealand, 18.8% of 26 year-olds have been found to have IBS using Manning’s 
diagnostic criteria.91 In Australia, 8.9 % (using Rome II criteria)92 to 13% (using the 
Manning criteria)93 of adults aged 18 and over (average age 45 years old) have been 
reported to have IBS.  
Currently, data on FODMAP intake of New Zealanders are lacking. A cross-sectional 
study of 50-year-old Cantabrians in New Zealand94 found mean intakes of 22.9g/d 
fructose, and 14.6g/d lactose. These are comparable with the average intakes of New 
Zealand population (21.4g/d fructose and 14/6g/d lactose).95 Incidentally, the study 
found an inverse relationship between IBS pain symptoms and intakes of fructose and 
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lactose. Neighboring country Australia has a habitual diet which consists of on 
average 16.4 g total FODMAPs, excluding fructose in excess of glucose (ranges 11.4 – 
21.8g), with 3.7g oligosaccharides (2.7 – 4.3g), 1.9g polyols (0.7 – 3.3g), 10.9g lactose (7 
– 15.1g) and 18.8g fructose (8.6 – 29.8).74    
2.3 Studies in older people 
 
2.3.1 Prevalence of IBS and intakes of FODMAP 
 
A random sample of noninstitutionalized Olmstead Country, Minnesota residents 
(aged 65 – 93 years) assessed using a mailed questionnaire found 10.9 per 100 person 
(95% CI, 7.2 – 14.6) with symptoms compatible with IBS using Manning’s criteria.96 
Additionally, the prevalence of frequent abdominal pain was 24.3 per 100 person, 
chronic constipation and diarrhea was 24.1 and 14.2 respectively and fecal 
incontinence of 3.7 per 100 persons was found.96 This study therefore suggests that 
prevalence of IBS is equally common in older people. A prevalence of 6 – 18 % was 
seen in a random sample of 70-year-old Danish population,  however, 50 – 79% of 
these participants who originally had IBS no longer did at 5-year follow-up point.97  
Minocha et al98 found IBS occurrence of  7.6% in the older group (≥ 50 years) and 9.9 % 
in the younger group (< 50 years) using Rome II criteria.  Prevalence of IBS in residents 
living in long-term care facilities is unknown. Similarly, there are no previous studies 
which had assessed the intakes of FODMAPs in older people nor the impact of low 
FODMAP diet on IBS in this group of adults.   
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2.4 Dietary assessment in older adults 
 
 2.4.1 Methods of dietary assessment 
 
There are five main dietary assessment methods used to assess food consumption of 
individuals. These methods are summarized in Table 5 with limitations for use in 
older people.  
Table 5. Dietary assessment methods and limitations 
Methodsa Limitations 
24-hour recall – asks subjects to recall exact 
food intake during the previous 24 – hour 
period or preceding day.  
Relies on subjects’ ability to recall. Not 
suitable for older people with cognitive 
impairment or dementia.  
Estimated food record – asks subjects to 
record at the time of consumption, all 
foods, fluids and snacks using household 
measures with details of brands and 
cooking methods. To estimate usual intake 
of an individual, weekend days should be 
proportionately included.  
High respondent burden. Requires literacy 
and ability to write. Introduces errors in 
quantifying portion sizes and converting 
volumes to weights.  
Weighed food record – all foods and 
beverages consumed are weighed, 
including details such as brands, 
description and food preparation methods.  
High respondent / investigator burden, 
requires numeracy as well as literacy. 
However, most suitable method for 
estimating nutrient intake of aged care 
residents given it is conducted by a trained 
investigator.    
Dietary history – used to estimate the usual 
food intake and meal pattern of individuals 
over a relatively longer period of time (e.g. 
a month). Allows to measure more habitual 
intake.  
Labor intensive, and requires a trained 
investigator to ask necessary questions. 
Relies on memory of the subjects to provide 
accurate estimate of the habitual intake.  
Food frequency questionnaire – assesses 
frequency of food or food groups consumed 
during a specified time period. Most 
questionnaires take 15 – 30 min to complete. 
Not suitable for older adults with poor 
memory or dementia.   




The biggest limiting factor for choosing the appropriate dietary assessment method in 
older people is their ability to accurately recall foods. Therefore, retrospective 
methods such as 24-hour recall, dietary history and food frequency questionnaire are 
not suitable for use in an aged-care setting as subjects with cognitive impairment will 
need to be excluded from the study which can be a significant proportion of the 
residents. Food records, particularly weighed food records (prospective methods) are 
considered the most accurate method of assessing usual intake.99 However, due to its 
high respondent burden, this method is not suitable for residents or the staff to 
conduct unless conducted by a trained research investigator.  
Two New Zealand based long-term residential care studies have both used weighed 
3-day diet records (3DDRs) of all main meals, daytime snacks and beverages including 
oral nutritional supplements to collect dietary intake data by a trained research 
assistant.100,101 Details of evening snacks and foods consumed outside of the facility 
were collected using food diaries and interviewer-administered food recalls in the 
calcium study,101 while the iodine study100 used staff to record supper and residents to 
recall anything that may have been missed over the 24 hour period or throughout the 
evening.   
Direct observation is an underused method where a trained personnel observes food 
intake behavior and estimates food intake. Previous studies have shown direct 
observation was effective in assessing dietary intake of children.102,103 In a residential 
care setting, Shatenstein et al104 found that there were no differences between visual 
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estimation (where plate wastage and percentage eaten of each food item was visually 
estimated) and weighed intakes of residents’ meals when conducted by motivated, 
trained observers. Furthermore, dietary intakes of nursing home residents 
documented by research staff using direct observation and photography methods 
were similar while nursing home staff documentation had significantly overestimated 
(by 22%) the residents’ intake.105 Therefore, based on these previous studies, direct 
observation and estimation of food intake using photography can be substituted for 
weighed diet records to observe residents’ dietary intake where one does not have to 








3. Objective statement 
 
Currently there are no New Zealand data on the frequency of GI symptoms in the 
elderly. The overarching aim of this study is to assess the number of residents in a 
residential care facility who are suffering from IBS-like symptoms, particularly 
residents with diarrhoea or incontinence and to understand whether FODMAP intake 
is associated with IBS symptoms. Therefore, the objectives of this study are to: (i) 
describe the frequency of GI symptoms in RH, H and FL residents of a retirement 
village, (ii) to determine the nature and quantity of commonly consumed high 
FODMAP foods by the RH and H residents, (iii) assess individual FODMAP intake of 
RH and H residents and (iv) investigate any association between FODMAP intake and 
IBS symptoms in RH and H residents.  
3.1 Hypothesis 
We hypothesise that: (i) the frequency of GI symptoms are greater among H residents 
compared to RH residents due to reduced functional abilities, (ii) majority of residents 
at the RH and H will have a high FODMAP intake and (iii) there is a positive 
correlation between FODMAP intake and total symptom score in the group of 
residents identified to have IBS-like symptoms.        _   
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4. Participants and methods 
 
4.1 Study design and participants 
This study is an exploratory cross-sectional observational study based at a single 
residential care facility in Christchurch, New Zealand. A retirement village of suitable 
size that was geographically near to the university was selected from a list of facilities 
operated by one of New Zealand’s largest retirement village and rest home operators, 
Ryman Healthcare. One hundred and twenty eight rest home (RH) and hospital-level 
of care (H) residents and 133 free-living (FL) residents living independently in 
apartments within the retirement village were invited to take part in the study. All 
volunteer participants were asked to read the participant information sheet 
(Appendix B) and sign the consent form (Appendix C) if interested to take part in the 
study. Written consent from the next of kin or the legal representative were sought for 
those residents with cognitive impairment. Each volunteer participant was then 
assigned a participant number. Recruitment and data collection was conducted over 
six months between July 2015 and January 2016. During this time, two outbreaks of 
gastroenteritis took place at the facility. Data collection was paused during these 
periods until residents were symptom-free and the affected study participants had 
recovered from vomiting and/or diarrhoea. Ethics approval was obtained through The 
University of Otago Human Ethics (Health) Committee (H15/053, Appendix D).  
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4.2 Gastrointestinal symptoms  
A validated Gastrointestinal Symptom Rating Scale modified for use in patients with 
IBS (GSRS-IBS) questionnaire106 was used (permission obtained from AstraZeneca) to 
identify residents with IBS-like symptoms. This particular questionnaire was selected 
over other self-assessment instrument as it is validated, disease-specific to IBS, short, 
user-friendly and it is widely used. The questionnaire contains 13 questions on GI 
symptoms which can be grouped into five domains; abdominal pain, bloating, 
constipation, diarrhoea and satiety. Responses of perceived severity of each symptom 
experienced in the past week are given in 1 to 7 Likert scale where 1 is “no discomfort” 
and 7 is “very severe discomfort”. Possible scores range from 13 to 91. An additional 
six questions related to dyspepsia and indigestion from the original GSRS107 were 
added to the questionnaire, allowing a range of scores from 19 to 133. Additionally, 
demographic data (date of birth, gender and ethnicity) and whether or not the 
respondents had assistance with completing the questionnaire were recorded.  The 
final questionnaire containing 19 questions will be referred to as the GSRS 
questionnaire (Appendix E) from this point onwards.  
For those FL residents, the GSRS questionnaire which was pre-labelled with 
participant number was posted to each apartment and a drop-off box was arranged in 
the facility’s main reception to return the completed questionnaire along with the 
consent form. A follow-up letter with copies of the questionnaire, participant 
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information and the consent form was posted three months later to those FL residents 
who did not respond to the first study invitation.  
The RH and H residents were interviewed face-to-face by the candidate using the 
GSRS questionnaire. A registered nurse verified responses of residents with mild 
short-term memory loss. A registered nurse familiar with the residents completed the 
GSRS questionnaire for those residents with dementia. The residents’ bowel charts 
were cross-referenced for frequency and types of bowel movements for that week. 
Eligible residents had to be aged over 65 years old, however, respite or temporary 
residents, residents receiving enteral feeding and those considered to be end-of-life 
were excluded from taking part in the study.  
4.3 Health information  
Health information on weight, height, body mass index (BMI), medical history, 
prescribed medications and functional status (continence, mobility and eating) were 
also collected from individual clinical notes for RH and H residents. This information 
is recorded on the health information sheet (Appendix F) with the corresponding 
participant number.  
The medical conditions were coded under ten different comorbidities: cardiovascular 
system (e.g. stroke, heart disease, and hypertension), musculoskeletal (e.g. fractures 
and osteoporosis), central nervous system (e.g. stroke and epilepsy), cognitive (e.g. 
dementia and memory losses), cancers, respiratory (e.g. asthma and chronic 
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obstructive pulmonary disease), psychiatric (e.g. depression and anxiety), lower GI 
(e.g. diverticular disease and constipation), diabetes, and thyroid disorders.       
Each list of medications was checked by a physician and regular drugs that were used 
for the treatment of constipation (e.g. laxsol and glycerine suppositories) and 
diarrhoea (e.g. loperamide and codeine phosphate) were coded as such. Furthermore, 
medications known to cause constipation (e.g. morphine elixir and quetiapine) or 
diarrhoea (e.g. metformin) as a side effect were also coded as such. 
4.4  Symptomatic and asymptomatic residents 
Currently there is no standardised “cut-off” level for identifying people with IBS using 
the GSRS-IBS. Rest home and hospital level of care residents were therefore ranked 
according to total IBS score (sum of responses to the 13 IBS questions in the 
questionnaire) from highest to lowest score and the top 30 high IBS score residents 
were selected as the “symptomatic” group. These 30 residents were then age, sex and 
level of care (either rest home or hospital level) matched to 30 asymptomatic residents 
as the “asymptomatic” group.  
4.5 Rest home menu and dietary analysis 
A standard four week cycle (summer) menu with recipes were obtained from the rest 
home and macro- and micronutrient content of each recipe was analysed using 
FoodWorks 8 Professional Edition (version 8.0.3553, 2015, Xyris Software, Australia). 
New Zealand FOODfiles 2014 and NUTTAB 2010 food files were used within 
FoodWorks. The FODMAPs database from Monash University, Department of 
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Gastroenterology, Melbourne, Australia was used to analyse carbohydrate foods 
within each recipe for the FODMAPs content in April 2016. Not all foods and 
beverages were found in the current FODMAP data and the 10 most common 
substitutions made are listed in Table 6. Furthermore, confectionaries such as lollies 
and wine gums were not entered for FODMAPs analysis as the main ingredients are 
glucose syrup and sugar which are low in FODMAPs. Additionally, retention factors 
were not applied to ingredients or to the recipes for analysis.  
Table 6. Ten most common food or beverage items substituted to estimate FODMAP 
contents 
Food or beverage item Substitutions made to estimate FODMAP 
content 
Canned fruit in syrup (e.g. peaches, pears 
and apricot) 
Fresh fruit content plus sugar and water 
content as per the ingredients list on the can 
e.g. 60 % pears and 30% water and sugar 
Apple based flavoured fruit puree Apple sauce recipe 
All hard cheeses including Edam cheese Cheddar cheese 
Diet lemonade Regular lemonade (ingredients checked on 
the label and considered low FODMAP) 
Mousses  Only considered milk content for lactose 
Flavoured yoghurt Plain yoghurt used for lactose content 
Flavoured ice-cream Plain vanilla ice-cream used for lactose 
content 
Raspberry, plum and apricot jam Strawberry jam 
Various kinds of biscuits Either plain sweet biscuit or chocolate 
biscuit used 
Christmas cake Fruit cake 
 
To compare dietary intakes between symptomatic and asymptomatic groups, a 
combination of weighed/estimated/recalled three-day diet record (3DDR) was used. 
This involved weighing food items for small and standard serving sizes for each meal 
using a Salter Model 1010 electronic kitchen scale accuracy to within ± 1g (Salter 
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Housewares Ltd, UK, range 1 – 2000 g) and recorded on the recording sheets we 
designed (Appendix G). However, not all participants’ actual meals and left overs 
were weighed to minimise interruptions at meal services (hence the modified weighed 
records). Each resident’s meal was photographed before and after consumption (see 
Appendix H) and the proportions of each food or beverage item consumed were 
estimated (e.g. 25%, 50%, 100%) using these photographs.  The 3DDR were collected 
for 60 selected residents for three main meals, snacks (morning and afternoon tea and 
supper) and beverages. The recordings consisted of non-consecutive two weekdays 
and a weekend day. This method was used over other dietary assessment methods 
(such as diet history, food frequency questionnaire and 24-hour dietary recall) as  
1. recalling information can be difficult for some residents  
2. it was not feasible to rely on facility staff to accurately document food intake 
due to their work load and time constraints  
3. to minimise work load for the researcher and minimise the chances of not 
obtaining the necessary data because an average of eight residents’ food and 
beverage intakes were observed each day and not all residents being studied 
ate in the same room or location. 
“Meals provided” included all food and beverages provided by the rest home, but 
excluded foods that were consumed outside of the facility or brought in by the family 
members. “Meals consumed” included all foods and beverages actually consumed by 
the residents throughout the day. Family members were interviewed over the phone 
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to recall items and quantities of food consumed by the study participants outside of 
the residential care facility. Any foods or beverages consumed overnight following 
supper the night before were asked about at breakfast from the residents who could 
recall. The majority of residents did not consume anything after supper including 
those residents with dementia except for fluids which were measured using the jug of 
water, juices or lemonade sitting in each residents’ room. Nutrient analysis for each 
food record was completed as per the same methods used to analyse the rest home 
menu recipes. 
Additionally, AusBrands 2015 and Nutricia 2015 files were used in FoodWorks to 
include macro- and micronutrient analysis of oral nutritional supplements such as 
Fortisip and Ensure drinks. FODMAPs content of nutritional supplements were 
obtained through contacting each company, however, most supplements contained 
negligible amounts of FODMAPs.   
4.6 Statistical analysis 
Participant demographic data were presented as either means and standard 
deviations or number of participants n (%). Box and whisker plots, histograms and 
scatter plots (including R2 and p-values) were used to display results of total GSRS 
scores (sum score of all 19 questions), total GSRS-IBS scores (sum score of 13 IBS-
related symptom questions) and FODMAP intakes. Comparisons were made to 
investigate differences between levels of care, and gender for total and IBS scores 
using Kruskal-Wallis tests. Differences in responses to GSRS questions between 
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symptomatic and asymptomatic groups were presented as median scores (range) and 
reports of any symptoms/discomfort (determined as score ≥ 2) or significant 
discomfort (score ≥ 4) were displayed as n (%).  
Residents who ate out and missed one or more main meals (either breakfast, lunch or 
dinner) from the facility were excluded from the final dietary analysis. Results of total 
energy, macronutrients (protein, fat, and carbohydrates), water, dietary fibre, and 
micronutrients (calcium and iron) intake and FODMAP (oligosaccharides, polyols, 
fructose in excess of glucose, lactose, total FODMAPs with and without lactose) intake 
were presented as the three-day average of all participants and range. Protein, water, 
dietary fibre, calcium and iron intakes were compared against the Nutrient Reference 
Values for Australia and New Zealand.108 Proportions (%) of food consumed were 
determined for each nutrient by subtracting mean of each nutrient “consumed” from 
“provided”. Paired t-tests were used for comparisons between “meals provided” and 
“meals consumed” and two sample t-tests were used for comparisons between 
symptomatic and asymptomatic groups. A p-value of  <0.05 was considered 
statistically significant. Fisher’s exact test was used to determine statistical differences 
between symptomatic and asymptomatic groups  for different cut-offs of total 
FODMAP intake (<5g, <4g, and <3g). These cut-offs were used as diet is considered 
low in FODMAPs if total FODMAP is less than 3g per day.74  
A simple linear regression adjusted for age, gender and levels of care was used to 
determine the relationship between total GSRS-IBS score and total FODMAP intake. 
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All statistical analyses were performed using RStudio (version 0.99.903, 2009-2016, 





5.1 Response rate and data used for analysis 
 
Figure 1 provides an overview of recruitment. One hundred and twenty eight RH and 
H residents were aged over 65 years old were resident at the facility. Five of these did 
not meet the inclusion criteria (respite care, end-of-life, enteral feeding) and three died 
during the data collection period. Of the 116 eligible RH and H care residents, 74  
(64%) completed the 19 question-based GSRS questionnaire and of the 133 eligible FL 
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Rest home and Hospital level of care 
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more main meals 
from the facility 
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3 missed one or 
more main meals 




5.2 Sample characteristics of the rest home and hospital level residents 
 
Characteristics of the 74 RH and H and 51 FL residents who completed the GSRS 
questionnaire are summarised in Table 7. The average ages were similar across the 
levels of care with 86 ± 6.6 years for RH and H combined and 85 ± 5.7 years for FL 
residents. The majority of the residents were females (72% and 69% respectively) and 
all Caucasians. In RH and H residents, none were diagnosed with IBS, however, 20% 
had a diagnosis of lower GI disorders and one in three residents (34%) had a 
recognised cognitive impairment. Just over half of the residents were on regular 
medications daily for the treatment of constipation and 69 residents (93%) were 




Table 7. Characteristics of the study participants 
Characteristics 
RH & H residents 
n = 74 
FL residents 
n = 51 
Age, mean ± SD in years 86 ± 6.55 85 ± 5.70 
Gender   
     Men 21 (28%) 16 (31%) 
     Women 53 (72%) 35 (69%) 
Ethnicity   
     NZ European 66 (89%) 47 (92%) 
     Other 8 (11%) 4 (8%) 
Level of care    
     Rest Home 34 (46%) 
     Hospital 40 (54%) 
Body mass indexa 
    Underweight (< 18.50 kg/m2) 10 (14%) 
     Normal (18.50 – 24.99 kg/m2) 37 (50%) 
     Overweight (25.00 – 29.99 kg/m2) 21 (28%) 
     Obese (≥ 30.00 kg/m2) 6 (8%) 
Regular medications 
     Treatment of constipation 38 (51%) 
     Treatment of diarrhoea 8 (11%) 
     Known to cause constipation 23 (31%) 
     Known to cause diarrhoea 5 (7%) 
Comorbidities 
     Cardiovascular 55 (74%) 
     Central nervous 39 (50%) 
     Respiratory 19 (26%) 
     Thyroid 8 (11%) 
     Musculoskeletal 42 (57%) 
     Diabetes 14 (19%) 
     Cognitive 25 (34%) 
     Psychiatric 17 (23%) 
     Cancer 22 (30%) 
     Lower GI disorder 15 (20%) 
Function levels 
     Continent of bowels 53 (72%) 
     Partial continence 5 (7%) 
     Incontinent 15 (20%) 
     Colostomy 1 (1%) 
     Able to mobilise 54 (73%) 
     Bed/chairbound 20 (27%) 
     Normal swallow 64 (86%) 
     Dysphagia (on pureed diet) 10 (14%) 
Notes: aWHO age-independent BMI classification109 




5.3 GSRS analysis of rest home and hospital level of care residents 
 
Sixty nine residents (93%) were interviewed by the main researcher face-to-face, using 
the GSRS questionnaire. Where residents had memory difficulties (n=16), their 
responses were checked by a nurse for accuracy. Five residents’ (6%) GSRS 
questionnaires were completed by the nurses due to cognitive impairment.  
Figure 2 summarises the distribution of total GSRS (A) and GSRS-IBS (B) scores of the 
participants. The median (and range) for total GSRS and total GSRS-IBS scores were 
23.5 (19 – 51) and 16.5 (13 – 40) respectively. Additionally, the first and third quartiles 
were 21 and 28.75 and 14 and 21 respectively for total GSRS and total GSRS-IBS scores.  
Figure 2. Histograms of total GSRS scores (A) and GSRS-IBS scores (B) of 74 study 
participants 







Fourteen percent of RH and H residents reported no GI symptoms in the GSRS 
questionnaire and the median number of symptoms reported was 3 (Table 8). 
Furthermore, one fifth (20%) of the residents had over 5 IBS symptoms.  
Table 8. Number of gastrointestinal symptoms reported by 74 rest home and hospital 
level residents 
 Q1 – Q13 (IBS symptoms) Q1 – Q19 (all GI symptoms) 
Median (range) 2 (0-9) 3 (0 – 13) 
0 symptoms, n  15 (21%) 10 (14%) 
1 symptom, n 14 (19%) 14 (19%) 
2 symptoms, n 12 (16%) 10 (14%) 
3 symptoms, n 10 (14%) 12 (16%) 
4 symptoms, n 4 (5%) 5 (7%) 
5 symptoms, n 4 (5%) 4 (5%) 
6 symptoms, n 8 (11%) 4 (5%) 
7 symptoms, n 2 (3%) 4 (5%) 
8 symptoms, n 4 (5%) 2 (3%) 
9 symptoms, n 1 (1%) 5 (7%) 
10 symptoms, n 0 2 (3%) 
11 symptoms, n 0 0 
12 symptoms, n 0 1 (1%) 
13 symptoms, n 0 1 (1%) 
5 or less symptoms 59 (80%) 55(74%) 
6 to 10 symptoms 15 (20%) 17 (23%) 
Over 10 symptoms 0 2 (3%) 
Abbreviations: IBS, irritable bowel syndrome; GI, gastrointestinal. 
 
A breakdown of number of residents reporting any discomfort from symptoms listed 
in GSRS questionnaire is summarised in Table 9 and responses to those 19 questions 
are depicted in Figure 3. For all 74 residents, the median score for all questions was 1. 
Collectively, the most common GI symptoms being bloating-related (53%) and upper 
GI-related symptoms (51%) as shown in Table 9. Thirty eight percent of residents 
reported either constipation or hard stools, however, a larger proportion of residents 
(46%) reported experiencing diarrhoea-related symptoms. Of the residents reported 
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to have diarrhoea- or constipation-related symptoms, 16 – 18% reported having 
moderate to severe discomfort. Individually, the most common symptoms were 
passing gas, followed by constipation and loose stools (Figure 3).  
Table 9. 74 rest home and hospital level residents reporting any and moderate to severe 
discomforts in GSRS questionnaire  
 GSRS score 
GSRS subdomains and 
individual questions 
≥ 2 (any 
discomfort, n 
(%)) 
≥ 4 (moderate 
to severe 
discomfort)  
Pain (Q1 or 2) 16 (22%)  11 (15%) 
Q1 abdo. pain 16      11 
Q2 pain relieved by BM 8 3 
Bloating (Q3, 4 or 13) 39 (53%) 6 (8%) 
Q3 bloating 22 5 
Q4 passing gas 28 4 
Q13 abdo. distention  6 0 
Constipation (Q5 or 8) 28 (38%) 13 (18%) 
Q5 constipation 25 9 
Q8 hard stools 16 7 
Diarrhoea (Q6, 7, 9 or 10) 34 (46%) 12 (16%) 
Q6 diarrhoea 7 2 
Q7 loose stools 24 4 
Q9 urgency 13 7 
Q10 incomplete BM 16 7 
Satiety (Q11 or 12) 22 (30%) 5 (7%) 
Q11 early satiety 16 4 
Q12 prolonged satiety 10 2 
Upper GI (Q14 – 19) 38 (51%) 7 (9%) 
Q14 heartburn 8 2 
Q15 acid regurgitation 8 0 
Q16 sucking sensation 4 1 
Q17 nausea vomiting 4 2 
Q18 abdo. rumbling 23 2 
Q19 belching 14 1 
Abbreviations: GSRS, Gastrointestinal Symptom Rating 
Scale; abdo., abdominal; BM, bowel movement; GI, 
gastrointestinal. 
Notes: n (%) for each of six subdomains (highlighted) was 
determined by adding number of residents who scored ≥2 or 




Figure 3. Bar graph of Likert score for 19 questions in GSRS questionnaire completed by 











Figure 4 is a comparison between RH and H residents for total GSRS and total GSRS-
IBS scores. The majority of residents in both levels of care scored less than 40 for total 
GSRS and the medians (and ranges) were similar at 22 (19 – 51) and 24.5 (19 – 51) for 
the RH and H residents respectively. The first and the third quartiles for RH and H 
were 20 and 33, and 21 and 28 respectively for total GSRS. Medians (ranges) for total 
GSRS-IBS score for RH and H were 15 (13 – 33) and 17 (13 – 40), respectively. 
Similarly, the lower and the upper quartiles were 13 and 22, 15 and 20, respectively.    
Figure 4. Histograms of total GSRS (A) and total GSRS-IBS (B) scores for 34 rest home 
(red) and 40 hospital level of care residents (blue) and any overlay in purple. 
              










Figure 5 displays the differences in total GSRS score and total GSRS-IBS score between 
male and female residents. A wider range was seen in females for total GSRS and 
GSRS-IBS scores, however, the mean scores were slightly higher in male with one or 
two outliers towards high scores for both gender. No significant patterns were seen 
between age and total GSRS score and GSRS-IBS score (Figure 6).      
Figure 5. Box and whisker plots of total GSRS (A) and GSRS-IBS (B) scores separated for 
21 male and 53 female residents 
   
 










Table 10 and Figure 7 show the reporting differences between RH and H residents for 
the 19 GSRS questions. When responses were categorised into the six domains, 
proportions of residents with symptoms are similar between RH and H, however over 
half of H residents reported having bloating or upper GI discomforts.  However, at 
individual question level, a larger proportion of H residents complained of discomfort 
with bloating (Q3, n=17, 42.5%) compared to RH residents (n=5, 14.7%). The 




Table 10. Differences between 34 rest home and 40 hospital level of care residents 
reporting any symptoms, and moderate to severe symptoms, for six subdomains within 
the GSRS questionnaire 
 Rest home residents (n=34) Hospital residents (n=40) 
GSRS subdomains and 
individual questions§ 
≥ 2 (any 
discomfort, n 
(%)) 




≥ 2 (any 
discomfort, n 
(%)) 




Pain (Q1 or 2) 7 (21%) 5 (15%) 9 (23%) 6 (15%) 
Q1 abdo. pain 7      5 9 6 
Q2 pain relieved by BM 4 1 4 2 
Bloating (Q3, 4 or 13) 14 (41%) 2 (6%) 25 (63%) 4 (10%) 
Q3 bloating 5 1 17 4 
Q4 passing gas 10 1 18 3 
Q13 abdo. distention  3 0 3 0 
Constipation (Q5 or 8) 12 (35%) 6 (18%) 16 (40%) 7 (18%) 
Q5 constipation 11 3 14 6 
Q8 hard stools 7 5 9 2 
Diarrhoea (Q6, 7, 9 or 10) 15 (44%) 6 (18%) 19 (48%) 6 (15%) 
Q6 diarrhoea 2 1 5 1 
Q7 loose stools 12 2 12 2 
Q9 urgency 9 4 4 3 
Q10 incomplete BM 7 4 9 3 
Satiety (Q11 or 12) 9 (26%) 2 (6%) 13 (33%) 3 (8%) 
Q11 early satiety 6 1 10 3 
Q12 prolonged satiety 5 1 5 1 
Upper GI (Q14 – 19) 14 (41%) 3 (9%) 24 (60%) 4 (10%) 
Q14 heartburn 3 0 5 2 
Q15 acid regurgitation 3 0 5 0 
Q16 sucking sensation 4 1 0 0 
Q17 nausea vomiting 2 1 2 1 
Q18 abdo. rumbling 10 2 13 0 
Q19 belching 4 0 10 1 
Abbreviations: GSRS, Gastrointestinal Symptom Rating Scale; abdo., abdominal; BM, bowel 
movement; GI, gastrointestinal.  
Notes: §Responses to all 19 questions had a median of 1 for both rest home and hospital level 
of care.  
n (%) for each of six subdomains (highlighted) was determined by adding number of residents 






Figure 7. Comparison between rest home and hospital level residents in Likert score for 




Figure 8 describes the frequency of individual GSRS scores of constipation (Figure 
8.A), hard stools (Figure 8.B), diarrhoea (Figure 8.C) and loose stools (Figure 8.D) 
separately between RH and H residents. The majority of RH and H residents (94% and 
88% respectively) reported no diarrhoea. In contrast, a greater number of RH and H 
residents complained of minor to severe forms of constipation (32% and 35% 
respectively) and hard stools (21% and 23% respectively). More H residents had 
experienced moderate to severe discomfort from constipation (15% as opposed to 9% 
in RH) while more RH residents experienced moderate to severe discomfort from hard 
stools (15% as opposed to 5% in H). 
Figure 8.  Histograms of constipation (A), hard stools (B), diarrhoea (C), and loose stools 
(D) scores compared between rest home (red) and hospital (blue) residents where purple 









5.4 GSRS analysis of free-living residents  
 
Table 11 compares the differences between median total GSRS and GSRS-IBS scores 
across the three levels of care; RH , H and FL. The results are further broken down to 
show gender differences, however, no statistically significant differences were noted.  
Table 11. Comparisons of GSRS scores across the three levels of care and gender 
differences 









Total GSRS  
Median (range) 24 (19 – 63) 22 (19 – 51) 24.5 (19 – 51) 0.72 
IBS  























Total GSRS  
Median (range) 
25  
(19 – 49) 
24  
(19 – 63) 
23  
(19 – 35)   
22  
(19 – 51)  
24  
(19 – 51) 
25  




(13 – 39) 
17  
(13 – 52) 
15  
(13 – 29)  
16  




(13 – 40) 0.86 
Abbreviations: RH, rest home; H, hospital level of care; FL, free-living residents; GSRS, gastrointestinal 
symptom rating scale; IBS, irritable bowel syndrome. 
Notes: a Kruskal-Wallis tests 
 
The most common symptoms among FL residents were diarrhoea-related symptoms 
(59%) followed by bloating- (57%) and upper GI-related symptoms (53%) (Table 12). 
One quarter and one fifth of residents reported moderate to severe discomfort for 
diarrhoea- and bloating-related symptoms, respectively. The proportion of FL 
residents experiencing abdominal pain, constipation and diarrhoea were higher than 
the RH and H residents. Figure 9 depicts breakdown of Likert scores for each 19 
question reported by FL residents. At individual question level, passing gas, 
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incomplete bowel motion and constipation were the three common symptoms 
reported.  
Table 12.  Reporting of any and moderate to severe discomfort by 51 free-living residents 
in the GSRS questionnaire 
 GSRS score 
GSRS subdomains and 
individual questions 
≥ 2 (any 
discomfort) 
≥ 4 (moderate 
to severe 
discomfort)  
Pain (Q1 or 2) 19 (37%) 7 (14%) 
Q1 abdo. pain 16 3 
Q2 pain relieved by BM 16 6 
Bloating (Q3, 4 or 13) 29 (57%) 10 (20%) 
Q3 bloating 15 5 
Q4 passing gas 23 10 
Q13 abdo. distention  12 2 
Constipation (Q5 or 8) 24 (47%) 10 (20%) 
Q5 constipation 21 9 
Q8 hard stools 7 2 
Diarrhoea (Q6, 7, 9 or 10) 32 (59%) 13 (25%) 
Q6 diarrhoea 10 3 
Q7 loose stools 18 6 
Q9 urgency 18 8 
Q10 incomplete BM 23 7 
Satiety (Q11 or 12) 14 (27%) 5 (10%) 
Q11 early satiety 10 3 
Q12 prolonged satiety 12 4 
Upper GI (Q14 – 19) 27 (53%) 4 (8%) 
Q14 heartburn 12 1 
Q15 acid regurgitation 13 1 
Q16 sucking sensation 1 0 
Q17 nausea vomiting 3 0 
Q18 abdo. rumbling 16 2 
Q19 belching 12 2 
Abbreviations: GSRS, Gastrointestinal Symptom Rating 
Scale; abdo., abdominal; BM, bowel movement; GI, 
gastrointestinal. 
Notes: n (%) for each of six subdomains (highlighted) was 
determined by adding number of residents who scored ≥2 or 





Figure 9. Bar graph of Likert score for 19 questions in GSRS questionnaire completed by 





5.5 Characteristics of “symptomatic” and “asymptomatic” groups of RH and 
H residents  
 
Table 13 shows that the 30 symptomatic residents appropriately matched for age, 
gender and level of care with asymptomatic residents. Figure 10 is a histogram 
showing a GSRS-IBS cut-off score of 17 to distinguish residents with and without IBS 
symptoms.   
Table 13. Demographic characteristics of “symptomatic” and “asymptomatic” groups 
matched for age, gender and level of care 
  
High IBS score / 
“symptomatic” (n=30) 
Low IBS score / 
“asymptomatic” (n=30) 
Age, mean ± SD in years 85.47 ± 6.64 86.9 ± 6.53 
Gender     
Men 7 (23 %) 7 (23 %) 
Women 23 (77 %) 23 (77 %) 
Level of care     
Rest Home 13 (43 %) 13 (43 %) 
Hospital 17 (57 %) 17 (57 %) 
 







The median scores for each question and total GSRS-IBS and GSRS scores in the two 
groups are shown in Table 14. The median score for all 19 questions were 1 (no 
discomfort) for asymptomatic group, while the median scores were 2 for passing gas 
and loose stools in the symptomatic group. None of the residents in either 
symptomatic or asymptomatic group had scored 7 (very severe discomfort) for any of 
the questions.  
Table 14. Comparisons between “symptomatic” and “asymptomatic” groups for median 









Q1 abdo. Pain 1.5 (1 - 6) 1 (1 - 2) 
Q2 pain relieved by BM 1.0 (1 - 6) 1 (1 - 1) 
Q3 bloating 1.5 (1 - 6) 1 (1 - 4) 
Q4 passing gas 2 (1 - 6) 1 (1 - 3) 
Q5 constipation 1 (1 - 6) 1 (1 - 4) 
Q6 diarrhoea 1 (1 - 3) 1 (1 - 2) 
Q7 loose stools 2 (1 - 6) 1 (1 - 3) 
Q8 hard stools 1 (1 - 6) 1 (1 - 2) 
Q9 urgency 1 (1 - 5) 1 (1 - 3) 
Q10 incomplete BM 1.5 (1 - 6) 1 (1 - 1) 
Q11 early satiety 1 (1 - 4) 1 (1 - 4) 
Q12 prolonged satiety 1 (1 - 4) 1 (1 - 2) 
Q13 abdo. distention  1 (1 - 3) 1 (1 - 1) 
Q14 heartburn 1 (1 - 4) 1 (1 - 2) 
Q15 acid regurgitation 1 (1 - 3) 1 (1 - 2) 
Q16 sucking sensation 1 (1 - 3) 1 (1 -1) 
Q17 nausea vomiting 1 (1 - 6) 1 (1 - 3) 
Q18 abdo. Rumbling 1.5 (1 - 6) 1 (1 - 3) 
Q19 belching 1 (1 - 4) 1 (1 - 2) 
Total IBS score (Q1-13) 21.50 (17 - 40) 14.5 (13 - 17) 
Total GSRS score (Q1-19) 29.5 (23 - 51) 21 (19 - 25) 
Abbreviations: GSRS, Gastrointestinal Symptom Rating Scale; abdo., 
abdominal; BM, bowel movement. 
69 
 
As shown in Figure 11, a greater number of residents in the symptomatic group had 
mild to severe levels (scores ≥ 3) of constipation, hard stools, diarrhoea and loose 
stools compared to the asymptomatic group.   
Figure 11. Histograms of constipation (A), hard stools (B), diarrhoea (C), and loose stools 




The differences between responses to GSRS questionnaire between symptomatic and 
asymptomatic groups are summarised in Table 15. The average number of IBS 
symptoms reported by the symptomatic group was 5 (range 2-9 symptoms). While in 
the asymptomatic group, the average number was 1 (range 0-3). At least half of the 
residents in the symptomatic group had pain-, bloating-, constipation-, diarrhoea-, 
satiety- and upper GI-related symptoms. One third of the symptomatic residents had 





asymptomatic group, upper GI-related symptoms were the most common (37%) 
followed by constipation- (27%) and bloating-related symptoms (23%).   
Table 15. Comparisons between “symptomatic” and “asymptomatic” groups reporting 




Symptomatic group (n=30) Asymptomatic group (n=30) 
GSRS subdomains and 
individual questions 
≥ 2 (any 
discomfort) 
≥ 4 (moderate 
to severe 
discomfort)  
≥ 2 (any 
discomfort)  
≥ 4 (moderate 
to severe 
discomfort)  
Pain (Q1 & 2) 15 (50%) 11 (37%) 1 (3%) 0 
Q1 abdo. Pain 15 11 1 0 
Q2 pain relieved by BM 8 3 0 0 
Bloating (Q3, 4 & 13) 24 (80%) 3 (10%) 7 (23%) 1 (3%) 
Q3 bloating 15 3 5 1 
Q4 passing gas 16 2 4 0 
Q13 abdo. distention  6 0 0 0 
Constipation (Q5 & 8) 17 (57%) 8 (27%) 8 (27%) 3 (10%) 
Q5 constipation 14 6 8 3 
Q8 hard stools 14 6 1 0 
Diarrhoea (Q6, 7, 9 & 10) 24 (80%) 10 (33%) 6 (20%) 0 
Q6 diarrhoea 4 0 1 0 
Q7 loose stools 16 4 5 0 
Q9 urgency 8 6 3 0 
Q10 incomplete BM 15 6 0 0 
Satiety (Q11 & 12) 15 (50%) 3 (10%) 5 (17%) 2 (7%) 
Q11 early satiety 11 2 4 2 
Q12 prolonged satiety 8 2 1 0 
Upper GI (Q14 – 19) 23 (77%) 6 (20%) 11 (37%) 0 
Q14 heartburn 7 2 1 0 
Q15 acid regurgitation 6 0 1 0 
Q16 sucking sensation 3 0 0 0 
Q17 nausea vomiting 3 2 1 0 
Q18 abdo. Rumbling 15 2 7 0 
Q19 belching 10 1 2 0 
Abbreviations: GSRS, Gastrointestinal Symptom Rating Scale; abdo., abdominal; BM, bowel 





5.6 Dietary analysis of macro- and micronutrients in symptomatic and 
asymptomatic groups 
 
Only those residents (54 residents in total) who consumed all main meals at the facility 
during data collection were included in the analysis. Details of macronutrients 
(protein, fat and carbohydrates), total energy, water, fibre, calcium and iron provided 
and consumed by these residents as well as the relevant requirements are presented 
in Table 16. There were statistically significant differences (paired t-test, p<0.001) 
between the amounts provided and amounts consumed for all nutrients. The 
proportions of nutrients consumed compared to provided were 80 to 81% for energy, 
carbohydrates, fat, calcium and iron, and 77% to 78% for protein and fibre respectively. 
The least proportion consumed was water at 69% compared to the provided amount. 
Both the average iron provided and consumed appear to have met the Estimated 
Average Requirement (EAR) and was very close to the Recommended Daily Intake 
(RDI) based on data from modified 3DDR. The Adequate Intake (AI) of water and 
dietary fibre were not met and the average calcium provided and consumed also fell 





Table 16. Three-day average macro- and selection of micronutrients provided and 






AIa EARa RDIa 




(5313 – 11413) 
6470 
(2705 – 10162)† 




(35.50 – 90.71) 
50.11 
(13.29 – 79.25)† 
  65 46 81 57 
Total fat  
(g) 
81.58  
(43.76 – 121.96) 
66.02 
(18.98 – 104.67)† 




(144.5 – 311.6) 
178.91 
(52.88 – 291.62)† 




(1465 – 2986) 
1548.6 
(486.7- 2736.9)† 
3400 2800      
Dietary fibre  
(g) 
20.45 
(10.03 – 35.26) 
15.93 
(2.06 – 31.09)† 




(362.1 – 1265.2) 
632.0 
(153.3 – 1161.8)† 




(3.91 – 14.89) 
7.84 
(1.24 – 13.71)† 
  6 5 8 8 
Notes: aNutrient Reference Values for Australia and New Zealand108 for age range 70 and over years, 
bTotal water (food and fluids), †p-value = <0.001, (paired t-test) 
Abbreviations: AI, Adequate intake; EAR, Estimated average requirement; RDI, Recommended daily 





There were no statistical differences in nutrient intake between symptomatic and 
asymptomatic groups (Table 17). Additionally, no obvious patterns were seen 
between fibre intake and constipation score or diarrhoea score in either the 
symptomatic or asymptomatic group (Figure 12). 
Table 17. Three-day average intake of macro- and micronutrients consumed by 









mean (range) 6516 (2705 – 9899) 6487 (2870 – 10162) 0.95 
Protein (g) 
mean (range) 50.03 (13.29 – 75.51) 50.20 (24.57 – 79.25) 0.96 
Total fat (g) 
mean (range) 66.68 (22.73 – 97.45) 65.37 (18.98 – 104.67) 0.81 
Carbohydrate (g) 
mean (range) 178.28 (52.88 – 283.16) 179.55 (97.37 – 291.62) 0.92 
Water (g) 
mean (range) 1503.8 (486.7 – 2654.1) 1593.5 (869.6 – 2736.9) 0.39 
Dietary fibre (g) 
mean (range) 15.85 (3.10 – 27.74) 16.00 (2.06 – 31.09) 0.92 
Calcium (mg) 
mean (range) 613.7 (153.3 – 1161.8) 650.3 (328.5 – 1107.8) 0.53 
Iron (mg) 
mean (range) 7.46 (1.24 – 11.83) 8.22 (1.71 – 13.71) 0.33 
Notes: aTwo sample t-test 
 
Figure 12. Scatter plots of fibre intake and constipation score (A), fibre intake and 






5.7  Dietary analysis of FODMAP intake in symptomatic and asymptomatic 
groups 
 
Table 18 summarises the three-day average of 54 residents’ FODMAPs provided and 
actually consumed. The greatest FODMAP contributor in residents’ diet was lactose 
where on average 19.59 g was provided and 16.29 g consumed. Both total FODMAPs 
including and excluding lactose consumed were significantly lower than provided in 
meals (paired t-test, p <0.01). The proportion consumed were very similar across each 
type of FODMAP, ranging between 79 and 83%.  
Table 18. Three-day average of FODMAPs provided and consumed by 54 residents in 







Oligosaccharides (g) 3.34 (1.52- 6.49) 2.72 ‡ (0.71 – 5.44) 81% 
Polyols (g) 1.85 (0.26 – 8.01) 1.46  (0.06 – 7.84) 79% 
Fructose in excess of glucose (g) 1.56 (0.21 – 4.78) 1.27  (0.04 – 3.76) 81% 
lactose (g) 19.59 (2.63 – 37.68) 16.29 † (1.39 – 36.7) 83% 
Total FODMAPs with lactose (g) 26.34 (7.22 – 47.65) 21.74 ‡ (2.47 – 45.12) 83% 
Total FODMAPs without lactose (g) 6.75 (2.86 – 13.44) 5.45 ‡ (1.08 – 12.00) 81% 
Notes: †paired t-test, p-value <0.05, ‡paired t-test, p-value <0.01, aproportion of each FODMAP 





The histograms of total FODMAP intake (with and without lactose) of the 54 residents 
are shown in Figure 13. Including lactose in the total FODMAP intake, the histogram 
approximately follows a normal distribution. However, without lactose in the total 
FODMAP, the distribution shows a positive skew.  
Figure 13. Histograms of total FODMAP including lactose (left) and total FODMAP 






Table 19 compares the average FODMAPs consumed by symptomatic and 
asymptomatic groups. On average, the symptomatic group consumed slightly more 
of each FODMAP except for oligosaccharides, however, there was no significant 
differences in intake of FODMAPs between the two groups.  As lactose intake only 
affects people with IBS who malabsorb lactose, the total FODMAP intake excluding 
lactose may be a more useful measure.  





Symptomatic group (n=27) 
mean (range) 
Asymptomatic group (n=27) 
mean (range) 
Oligosaccharides (g) 2.65 (0.71 – 5.44) 2.79 (1.21 – 5.27) 0.65 
Polyols (g) 1.58 (0.06 – 7.84)   1.34 (0.10- 5.15) 0.54 
Fructose in excess of 
glucose (g) 1.30 (0.15 – 3.76) 1.24 (0.04 – 2.48) 0.78 
lactose (g) 16.50 (1.39 – 36.67) 16.08 (2.56 – 30.48) 0.85 
Total FODMAPs with 
lactose (g) 22.03 (2.47 – 45.12) 21.44 (6.74 – 34.64) 0.80 
Total FODMAPs 
without lactose (g) 5.53 (1.08 – 12.00) 5.37 (2.27 – 10.82) 0.81 





Table 20 describes the number of residents meeting the various Total FODMAP 
(excluding lactose) cut-off levels at 3g, 4g, and 5g between symptomatic and 
asymptomatic groups. All 7 residents who consumed less than 3 g total FODMAP 
were aged 90 and over. Two of the five symptomatic residents who consumed less 
than 3g FODMAP had consumed less than 50% of total energy and macronutrients, 
provided from food. 
Table 20.  Comparison of number of residents between symptomatic and asymptomatic 
group with total FODMAP intake (excluding lactose) cut off levels at 3g, 4g and 5g 
Total FODMAP 
intake 
Number of residents meeting the cut offs 
p-valuea Symptomatic group Asymptomatic group 
 < 3g 5 2 
0.42 ≥ 3g 22 25 
    
< 4g 9 7 
0.77 ≥ 4g 18 20 
    
< 5g 13 13 
1 ≥ 5g 14 14 
Notes: aFisher’s exact test 
 
Table 21 lists examples of foods contributing towards FODMAP intake. Milk and milk 
products such as milky puddings, and smoothies contributed largely to lactose intake. 
Wheat-based products such as muffins, scones, biscuits, pastries, bread, some cereals, 
as well as pasta, baked beans, peas, soups and some nutritional products contributed 
towards oligosaccharide intake. Intakes of polyols were largely from canned fruit, 
fruit salads, apple puree as well as vegetables such as corn, mushrooms and 
cauliflower. Canned pears as well as fruit salads, some breakfast cereals, and orange 
juice were main sources for excess fructose intake.  
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Table 21.  Examples of foods and recipes contributing to intakes of each FODMAP group 
FODMAPs 
Foods/recipes consumed that are largely 
contributinga 
Lactose milk for cereals, porridge (as made with milk), ice-
cream, yoghurt, desserts made with milk (e.g. 
mousses, custard, rice pudding, ambrosia), 
smoothie, and other (e.g. recipes such as macaroni 
cheese and broccoli/cauliflower with cheese 
sauce) 
Oligosaccharides Baked beans, fruit cake or Christmas fruit pies, 
toasted muesli, All bran cereals, weet-bix, 
nutritional supplements (e.g. Ensure powder, 
Diasip, and Two Cal) green peas, baked products 
(date loaf, muffins, scones, biscuits, pies, pastries, 
cakes, chocolate brownies and slices), bread, 
homemade soups (containing onion, other high 
FODMAP vegetables and flour),  pasta dishes, 
prunes, and commercial hot chips/wedges  
Polyols  Stewed prunes, canned fruitb (peaches, pears and 
apricot), apple puree, fresh or canned fruit salad, 
any recipes containing canned fruit (e.g. jellied 
fruit, smoothie, summer fruit crumble, ginger and 
pear sponge), apple danish or pie, mushroom 
recipes (e.g. creamy chicken and mushroom pasta, 
penne pasta carbonara, mushroom, onion and feta 
quiche, creamy mushroom soup), corn recipes 
(e.g. steamed corn kernels, corn chowder) and 
cauliflower cheese sauce 
Fructose in excess of glucose  Canned pearsb or recipes including canned pears 
(e.g. jellied fruit, ginger and pear sponge), fresh or 
canned fruit salad,  green peas, toasted muesli, all 
bran, orange juice, apple puree, apple danish/pie, 
baked beans, and asparagus soup  






5.8 Relationships between IBS symptom scores and FODMAP intake 
 
Figure 14 presents scatter plots of various GSRS-IBS symptom scores against total 
FODMAP (excluding lactose) intake between the symptomatic and asymptomatic 
groups. Regardless of the total FODMAP intake, none of the 27 asymptomatic 
residents reported abdominal pain, hard stools, incomplete bowel movement, and 
bloating. The only statistically significant relationship seen in the symptomatic group 






















Figure 14. Scatter plots of total FODMAP intake (excluding lactose) and various IBS 













Simple linear regression of total FODMAP (excluding lactose) intake and total GSRS-
IBS score adjusted for age, gender and level of care did not show any significant 
association (Figure 15A). No significant association was seen between GSRS-IBS score 
and total FODMAP intake of symptomatic subjects (data not shown). There was a 
significant association between total FODMAP intake and age (Figure 15B, p = < 0.01) 
but not with gender (Figure 15C) or the level of care (Figure 15D).  A further 
adjustment with diagnosis of lower GI disorder, medications used to treat or 
potentially cause constipation and diarrhoea did not significantly improve either the 
fit (R-squared value) or the statistical significance (p-value) of the relationship 
between total FODMAP intake and total GSRS-IBS score. Similarly no statistically 
significant relationships between total FODMAP and GSRS-IBS were obtained when 
top 25, 20, 15 and 10 symptomatic residents with their age, sex, and level of care 









Figure 15. Relationships between total FODMAP intake, excluding lactose and total IBS 
score (A), age (B), gender (C) and level of care (D) 
 
 
A further analysis shows that there is a statistically significant negative relationship 
between age and total energy intake (Figure 16A) and proportion of energy consumed 
(Figure 16B) similar to total FODMAP intake and age (Figure 15B). Additionally, there 
was a significant positive relationship between total energy and total FODMAP intake 
(p = 0.008, data not shown).    
Figure 16. Relationship between age and total energy consumed (A) and proportion of 







6. Discussion and conclusion 
 
6.1 Key findings 
This study did not show a significant association between total FODMAP intake and 
total GSRS-IBS scores in residents with GI symptoms consistent with IBS.  
There may be a number of reasons for no significant association being identified. 
Firstly, this may be a true finding and, in an elderly population, there is not an 
association between FODMAP intake and GI symptoms. Against this are the 
consistent findings of low FODMAP diet improving functional GI symptoms in 
multiple studies23, 68, 74-77 in younger adults. However, none of these studies have 
focused solely on older adults.  
Alternatively, there may be a number of limitations of study design that could have 
contributed to the null hypothesis being accepted. Firstly, the study may have been 
under-powered to show a significant effect. We have selected 30 residents out of total 
74 (41%) as having IBS-like symptoms, however, this proportion is much higher than 
what one would expect to see especially in this age group. The rates of GI symptoms 
in the elderly were not known before this exploratory study and if more patients with 
functional symptoms were included then this may have improved the chances of 
observing a true association. Secondly the selection of cases may not have been 
sufficiently rigorous. It was assumed that the presence of GI symptoms in this 
population may reflect functional GI symptoms consistent with IBS, but the patients 
may have been suffering from other causes of GI symptoms (such as those due to 
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comorbidities or their treatments, previous GI surgery, effects of immobility, etc.) for 
their symptoms that may be less likely to respond to a low FODMAP diet. 
Furthermore our “cut-off” level for symptomatic and asymptomatic group using the 
GSRS-IBS was 17. However, studies have shown that those patients (aged less than 65 
years of age) diagnosed by a medical professional with IBS typically have a higher 
total GSRS-IBS score ranging from 48.5 and 61.110,111 
Additionally, the average GSRS-IBS rating score for pre-diagnosed IBS patients for the 
individual symptoms are between 3 and 4112-114 in younger population (18 – 50 years 
old). In our study, we did not have any RH or H level residents who scored an average 
rating of 3 or above in GSRS-IBS in the symptomatic group. Even the top 10 high 
GSRS-IBS scored participants had an average GSRS-IBS score of 2.12 for the individual 
GI symptoms. Therefore, in comparison to these published results, it is plausible either 
that rates of IBS are much lower among long-term aged care residents or that due to 
multiple medications being prescribed, symptoms of IBS are masked or mostly 
managed through drugs. This latter explanation is more plausible as the majority of 
residents (93%) had laxatives prescribed for use if needed, and over half used these on 
daily basis. Additionally, the majority of residents had regular or as required pain 
killers prescribed for those residents in RH and H (results not shown). Similarly, some 
GI symptoms could also be caused by the medications.  
Differences in medication practices between dependent (R and H) residents and 
independent (FL) residents may potentially explain the surprisingly higher rates of 
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diarrhoea-related symptoms seen among FL residents. However, we cannot be sure 
this is the case as we did not collect information on medications from FL residents. 
Furthermore, only 38% of the FL residents completed the GSRS questionnaire. We 
believe those FL residents with few or no GI symptoms may be under-represented in 
this study. For example we received two blank GSRS questionnaires from the 
residents with a comment stating they were “healthy”. Hence there may be other 
residents who did not complete the questionnaire because they were “healthy” and in 
future studies using questionnaires, study participants should be made very clear that 
we want responses from everyone regardless of whether they experience any GI 
symptoms or not.  
The only significant relationship seen in the symptomatic group was between total 
FODMAP intake and hard stools. This result is consistent with what one would expect. 
Unless one is mindful of fibre intake while restricting FODMAP intake, one could 
experience hard stools or constipation.  
Halmos et al74 has described a low FODMAP diet comprising 1.57g of oligosaccharides, 
0.2g of polyols, 0.05g of lactose and 1.24g fructose in excess of glucose (total FODMAP 
of 3.05g per day). In the present study, the RH and H residents consumed substantially 
more FODMAPs except for fructose in excess of glucose. Seven residents (5 
symptomatic and 2 asymptomatic) consumed less than 3g. One explanation for this 
finding is that the residents have low intake of all foods (including FODMAPs) as they 
were all aged over 90 years. We found a significant negative relationship between age 
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and total energy intake as well as total FODMAP intake. Indeed two of the 
symptomatic residents were found to be consuming <50% of total energy and 
macronutrients. An alternative reason might be that these symptomatic residents are 
either intentionally or unintentionally avoiding foods high in FODMAP to avoid GI 
symptoms. Either way, these residents are potentially at high risk of malnutrition 
resulting from food restrictions. Limitations of the dietary assessment methodology 
used in this study are discussed in section 6.3.  
6.2 New knowledge 
To our knowledge, currently there are no published data on the frequency of GI 
symptoms of New Zealand adults over the age of 65 years. We believe, our study is 
the first to describe this using the validated GSRS-IBS questionnaire as most studies 
exclude older participants. To our knowledge, this study is also the first to describe 
FODMAP intake in older adults living in a long-term aged care facility and to observe 
the entire diet of participants in their own environment for FODMAP intake.  We have 
also investigated the frequency and volume of common high FODMAP foods 
consumed among RH and H residents. Only two published studies in New Zealand 
have assessed the nutrient intake of RH and H residents in aged care facilities but 
these have looked at micronutrients more specifically (iodine100 and vitamin D101). 
However, neither of these studies have published the general nutritional break down 
of macro and micronutrients as we have done in our study.  
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6.3 Strengths and weaknesses 
The strengths of this study are as follows. One researcher (the candidate) conducted 
all data collection and data entry to remove inter-investigator variation. The dietary 
intake was also collected using a modified weighed 3DDR to avoid errors of reporting 
by the participants, particularly under-reporting. Additionally, this method did not 
need to rely on residents’ memories (as 34% of RH and H residents participated in the 
study had a recognised cognitive impairment) except for food consumed between 
supper and breakfast. Furthermore, all recipes were collected from the main cooks 
and actual residents’ intakes were observed allowing better quality of data being 
entered for nutrient analysis rather than food diaries filled out by the residents or staff 
at the residential care facility. 
Limitations of the modified weighed 3DDR include errors from estimating the actual 
intake as left overs were not always weighed and instead estimated visually for each 
food item. Additionally, some recalling needed to be applied for food intakes between 
supper and breakfast the next morning. Although this will affect the accuracy of the 
nutrient analysis, we felt this dietary assessment method was most appropriate for 
our subjects and to minimise interruptions of the meal service. Furthermore, the 
recipes also did not take into account the retention factors from cooking processes 
which may have resulted in over-estimation of the nutrient intake. It is therefore 
concerning that certain nutrients such as calcium intake is low in this population 
despite the potential overestimation of nutrient intake. We cannot also exclude the 
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possibility of 3DDR being not enough to adequately represent the usual diet of the 
residents, particularly the micronutrients such as iron which are not as widespread 
throughout the diet as macronutrients therefore requiring more than three days of 
food records.99 However, given the large discrepancies between intake and 
recommendations for calcium intake, we can be reasonably confident that residents 
are not consuming adequate amounts of calcium.    
As explained above, we believe the study sample may have been underpowered to 
find any statistically significant differences between asymptomatic and symptomatic 
groups due to the small number of participants in the study. This in turn may have 
resulted in false negative (type 2) error for the relationship between FODMAP intake 
and GI symptoms. As only one residential care facility was included in the study, the 
results cannot be generalised to all older adults living in long-term care facilities. The 
demographics, specifically the ethnicity where all of the residents were Caucasian in 
this study is not representative of the New Zealand population.  
Other limitations include incomplete FODMAP analysis due to some food items not 
yet being analysed (such as canned fruit which needed to be substituted with fresh 
fruit with some proportions accounting for sugar and water content). There were also 
a few foods which the facility had commercially sourced and recipes for these items 
needed to be estimated. In this study, we have not considered FODMAP contents in 
certain medications which may have affected the GI symptoms particularly if taken 
on daily basis.  
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Finally, with regards to the validated GSRS-IBS questionnaire that was used, the 
candidate observed that some of the language was less than optimal and may have 
led to confusion for the participants. For example, the word ‘bothered’ could be 
changed. For instance, the phrases could be improved to “have you had constipation 
in the last one week” or “have you experienced any constipation in the last one week” 
rather than “have you been bothered by constipation in the last one week”. This is 
because some residents interviewed in this study reported experiencing symptoms 
however, also reported that they were not bothered by them. Also, what the 
respondents consider ‘constipation’ and ‘diarrhoea’ may vary and is subjective.   
Furthermore, it is difficult to explain why the authors who developed the GSRS-IBS 
categorised “sensation of incomplete bowel evacuation” as part of the “diarrhoea” 
subdomain as it could also result from constipation. Also, our intention is to capture 
the main GI symptoms, and this did not differentiate people suffering diarrhoea 
secondary to constipation (known as by pass or overflow diarrhoea).  Another 
limitation of this tool is the lack of standardised cut-off for determining patients with 
IBS.  
6.4 Future research 
A much larger study with multiple facilities around the country would be needed to 
produce more representative results of New Zealand long-term aged care residents. 
As there is no standardised cut-off for GSRS-IBS, future studies looking at prevalence 
of IBS among older adults may benefit from using the diagnostic criteria such as the 
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Rome III criteria for IBS, however, this requires a physician or  a medical professional 
qualified to diagnose patients. Special care is needed due to the age group being 
investigated, to rule out other serious diagnosis such as colorectal cancer. Published 
data on nutrition intake in this population is lacking. It would be interesting to 
investigate the cascade of nutrient intake from that planned through the menu 
provided by the facility to actual foods consumed by the residents for determining 
factors such as food wastage and proportion of final uptake by the residents. The 
outcomes can be used to plan dietary management to minimise malnutrition among 
aged care residents for instance. We also suggest developing a questionnaire that is 
better suited to older people for assessing GI symptoms. Our results indicated that 
both symptomatic and asymptomatic groups were consuming similar amount of 
FODMAPs. It is worth investigating whether a low FOMDAP diet would lead to 
reduced IBS-related GI symptoms in the symptomatic group.      
6.5 Practical application 
More research is needed to understand the relationship between FODMAP intake and 
IBS symptoms in older adults living in long-term care facilities. However this research 
has provided some basic information such as frequency of GI symptoms among RH, 
H and FL residents which can be used to raise awareness of significance of these GI 
symptoms among this population. Additionally, this study has highlighted the 
nutritional inadequacies of the foods provided to the residents, particularly fibre and 
calcium. Therefore it remains our interest to further investigate the nutritional 
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adequacy of the rest home menu in order to ensure sufficient quantities of macro and 
micronutrients are consumed by the elderly residents (the menu to mouth concept). 
The results from this study can be used to generate power calculations to determine 
the number of participants needed to accurately test these hypotheses. The medication 
practices within the study facility appears to be managing most residents’ GI 
symptoms satisfactorily. Hence, the current medication practices could be adopted by 
other facilities if they had significantly higher percentage of residents with GI 
symptoms. The commonly consumed high FODMAP foods by the RH and H residents 
can be used to amend recipes and menus in the future to develop low FODMAP 
alternative options for residents who might be suffering from IBS symptoms, 
particularly those residents with diarrhoea or faecal incontinence.   
6.6 Conclusion 
The current study is unique as it has generated the first data on the frequency of GI 
symptoms among older adults living in a retirement village, at three different care 
levels (RH, H and FL) in New Zealand. This study was also the first to investigate the 
relationship between FODMAP and IBS symptoms in the elderly (average age of 86 ± 
6.55 years old). It is likely the study was underpowered to detect any statistically 
significant differences due to low GSRS scores across the study population.  However,  
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Appendix B: Participant information sheet 
 
Participant Information Sheet 
Study title: Diet and Gut Symptoms in the Elderly 
Principal 
investigator: 
Dr. Paula Skidmore 
Department of Human 
Nutrition 
Senior Lecturer 




Thank you for showing an interest in this project.  Please read this information 
sheet carefully. Take time to consider and if you wish, talk with relatives or 
friends, before deciding whether or not to participate.  
If you decide to participate we thank you.  If you decide not to take part, there 
will be no disadvantage to you and we thank you for considering our request.   
What is the aim of this research project? 
The first aim of this project is to look at the frequency of gut symptoms in elderly 
New Zealanders. We would also like to determine the relationships between 
intake of fermentable carbohydrates and gut symptoms and whether diet low 
in such carbohydrates could improve the symptoms. Fermentable 
carbohydrates are sugars that are easily fermented in your digestive system 
causing gas, bloating, abdominal pain and altered bowel functions such as 
diarrhoea and / or constipation. Currently there are no studies that have looked 
at these variables. The results from this study can help us understand the 
significance of gut symptoms in the elderly population and possible dietary 
management for these symptoms.   
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Who is funding this project? 
This study is funded by the University of Otago.  
Who are we seeking to participate in the project? 
We are inviting all residents of Ngaio Marsh Retirement Village to participate in 
our study.   
If you participate, what will you be asked to do? 
Participation in this study is voluntary. We will ask all participants 15 questions 
related to gut symptoms. If you live in the retirement village, we will ask you 
some questions about you and your health. If you are a resident of the rest 
home or hospital part of Ngaio Marsh, we would like to ask for your permission 
to look at your medical file. This is to obtain information on weights, height, any 
medical condition that you have, medications list and your functional status 
(continence, mobility and eating). We will also observe and record three days of 
food and fluids you have consumed at the rest home over a course of a week. 
In addition, you will be asked to recall any foods and fluids you have consumed 
overnight between supper and breakfast. You may ask help from your family or 
the rest home staff to answer these questions. 
For families/carers: If you have responsibility for the care of a resident who is 
unable to give informed consent but you would like to take part in the study on 
their behalf, we would ask you to assist the resident with collection of the data. 
We would also ask you to sign the consent form on behalf of the resident.  
Is there any risk of discomfort or harm from 
participation? 
There is no risk of harm in participating. The questionnaire which contains 15 
questions about gut symptoms should take less than 20 minutes to complete.  
What specimens, data or information will be collected, 
and how will they be used?  
The data collected will be securely stored in such a way that only researchers 
actively involved in the study will be able to gain access. At the end of the study, 
any personal information will be destroyed immediately except that, as required 
114 
 
by the University’s research policy. Any raw data on which the results of the 
project dependent will be retained in secure storage for ten years, after which it 
will be destroyed.  
What about anonymity and confidentiality? 
The results of the study may be published and will be available in the University 
of Otago libraries but every attempt will be made to preserve your anonymity. 
You are most welcome to request a copy of the results of the project should 
you wish.  
If you agree to participate, can you withdraw later? 
You may withdraw from participation in the project at any time and without any 
disadvantage to yourself. 
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Wathsala Nanayakkara 
Student investigator 
Department of Human Nutrition 
Contact phone number: 
021-176-2651 
Dr Paula Skidmore 
Principal investigator 
Department of Human Nutrition 
Contact phone number: 
03-479-8374 
Professor Richard Gearry 
Research investigator 
Department of Medicine 
Contact phone number: 
03-364-0640 
Leigh O’Brien 
Consultant Dietitian for Ngaio Marsh 
Retirement Village and Rest Home 





This study has been approved by the University of Otago Human Ethics Committee 
(Health). If you have any concerns about the ethical conduct of the research you may 
contact the Committee through the Human Ethics Committee Administrator (phone 
+64 3 479 8256 or email gary.witte@otago.ac.nz). Any issues you raise will be treated 





Appendix C: Consent form for participants 
 
        Diet and Gut Symptoms in the Elderly 
Principal Investigator: Dr. Paula Skidmore (paula.skidmore@otago.ac.nz, 03 479 8374) 
CONSENT FORM FOR PARTICIPANTS 
Following signature and return to the research team this form will be stored in a 
secure place for ten years. 
 
1.  I have read the Information Sheet concerning this study and understand the 
aims of this research project. 
2.  I have had sufficient time to talk with other people of my choice about 
participating in the study.   
3.  I confirm that I meet the criteria for participation which are explained in the 
Information Sheet. 
4.  All my questions about the project have been answered to my satisfaction, 
and I understand that I am free to request further information at any stage.  
5.  I know that my participation in the project is entirely voluntary, and that I am 
free to withdraw from the project at any time without disadvantage. 
6.  I know that as a participant I will provide information about gut symptoms 
(all participants) and diet (rest home and hospital level care residents only). I 
give permission for the researchers to view my clinical records in the rest 
home to access information on weights, height, medical history, medications 
list, functional status and gut symptoms (rest home and hospital level care 
residents only).  
7.  I know that the interview-based questionnaire will explore the gut symptoms 
(all participants) and three days of food intake will be observed and recorded 
(rest home and hospital level care residents only). If the line of questioning 
develops in such a way that I feel hesitant or uncomfortable I may decline to 
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answer any particular question(s), and /or may withdraw from the project 
without disadvantage of any kind. 
8.  I understand the nature and size of the risks of discomfort or harm which are 
explained in the Information Sheet. 
9.  I know that when the project is completed all personal identifying 
information will be removed from the paper records and electronic files which 
represent the data from the project, and that these will be placed in secure 
storage and kept for at least ten years.  
10. I understand that the results of the project may be published and be available 
in the University of Otago Library, but I agree that any personal identifying 
information will remain confidential between myself and the researchers 
during the study, and will not appear in any spoken or written report of the 
study. 
11. I know that there is no remuneration offered for this study, and that no 
commercial use will be made of the data.  
12. I understand that the researchers may contact the GP if they have any 
concerns with their findings.  
Signature of participant:  Date: 
   
   
 
Where a participant cannot sign the consent themselves,  
I confirm that I am authorised to provide consent on behalf of __________________ 
and I have read and understood points 1 to 12 on the previous page. 
 
Signature of legal guardian  Date: 













Appendix E: Gastrointestinal symptom rating scale questionnaire 
 
Gastrointestinal Symptom Rating Scale (GSRS) 
 
 
Date of Birth __________    Gender_______   Ethnicity______________ 
 
Please tick the box if you had any assistance completing this 
questionnaire  
 
Circle the number which best represents the current severity of each 
symptom. 
 
1. Have you been bothered by abdominal pain during the past 
week?  
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
2. Have you been bothered by pain or discomfort in your abdomen, 
relieved by a bowel action during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 








3. Have you been bothered by a feeling of bloating during the past 
week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
4. Have you been bothered by passing gas during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
5. Have you been bothered by constipation (problems emptying the 
bowel) during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 











6. Have you been bothered by diarrhoea (frequent bowel 
movements) during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
7. Have you been bothered by loose bowel movements during the 
past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
8. Have you been bothered by hard stools during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 










9. Have you been bothered by an urgent need to have a bowel 
movement (need to go to the toilet urgently to empty the bowel) 
during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
10. Have you been bothered by a feeling that your bowel was not 
completely emptied after having a bowel movement during the past 
week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
11. Have you been bothered by feeling full shortly after you have 
started a meal during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 








12. Have you been bothered by feeling full even long after you have 
stopped eating during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
13. Have you been bothered by visible swelling of your abdomen 
during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
Please answer the next six questions if you have time.  
 
14. Have you been bothered by heartburn during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 









15. Have you been bothered by acid regurgitation during the past 
week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
16. Have you been bothered by sucking sensations in the upper 
abdomen during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
17. Have you been bothered by nausea and vomiting during the 
past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 











18. Have you been bothered by abdominal rumbling during the past 
week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 
7 Very severe discomfort 
 
19. Have you been bothered by belching during the past week? 
 
1 No discomfort at all 
2 Minor discomfort 
3 Mild discomfort 
4 Moderate discomfort 
5 Moderately severe discomfort  
6 Severe discomfort 


















Appendix F: Participant health information recording sheet 
Patient Health Information 
 
Date of Birth __________    Gender_______   Ethnicity______________ 
 
Current weight:  
 
Past weights:  
 






























Appendix G: 3-day food diary recording sheet 
Food record – Breakfast + any foods consumed overnight 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Cereals (type) + 
amount provided 
   
Amount actually 
consumed 
   
Toast (type) + amount 
provided 
   
Amount actually 
consumed 
   
Drinks (type) + 
amount provided 
   
Amount actually 
consumed 
   
Spreads (type) + 
amount provided 
   
Amount actually 
consumed 
   
Extra 1+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 2+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 3+ amount 
provided 
   
Amount actually 
consumed 




Food record – morning medications + morning tea 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Food item for 
medications + amount 
provided 
   
Amount actually 
consumed 
   
Baked products    
Amount actually 
consumed 
   
Other    
Amount actually 
consumed 
   
Beverages (type)+ 
amount provided 
   
Amount actually 
consumed 
   
Extra 1+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 2+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 3+ amount 
provided 
   
Amount actually 
consumed 





Food record – midday meal 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Main 1 (item) + 
amount/size provided 
   
Amount actually 
consumed 
   
Main 2 (item) + 
amount/size provided 
   
Amount actually 
consumed 
   
Main 3 (item) + 
amount/size provided 
   
Amount actually 
consumed 
   
Pudding 1 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Pudding 2 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Beverage (type) + 
amount provided 
   
Amount actually 
consumed 
   
Extra (type) + amount 
provided 
   
Amount actually 
consumed 





Food record – afternoon medications + afternoon tea 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Food item for 
medications + amount 
provided 
   
Amount actually 
consumed 
   
Biscuits (type) + 
amount provided 
   
Amount actually 
consumed 
   
Other    
Amount actually 
consumed 
   
Beverages (type)+ 
amount provided 
   
Amount actually 
consumed 
   
Extra 1+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 2+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 3+ amount 
provided 
   
Amount actually 
consumed 





Food record – evening meal 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Soup (type) + 
amount/size provided 
   
Amount actually 
consumed 
   
Main 1 (item) + 
amount/size provided 
   
Amount actually 
consumed 
   
Main 2 (item) + 
amount/size provided 
   
Amount actually 
consumed 
   
Bread (type) + 
amount/size provided 
   
Amount actually 
consumed 
   
Pudding 1 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Pudding 2 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Beverage (type) + 
amount provided 
   
Amount actually 
consumed 





Food record – supper 
Participant number: ___________________   Dates: ______________________ 
 Day 1 Day 2 Day 3 
Food item for 
medications + amount 
provided 
   
Amount actually 
consumed 
   
Food 1 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Food 2 (type) + 
amount provided 
   
Amount actually 
consumed 
   
Beverages (type)+ 
amount provided 
   
Amount actually 
consumed 
   
Extra 1+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 2+ amount 
provided 
   
Amount actually 
consumed 
   
Extra 3+ amount 
provided 
   
Amount actually 
consumed 
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Appendix H: Example meal photos 
 
Example 1: Breakfast provided (left, 200g porridge, 11g brown sugar, 25g white 
toast, 7g marmalade, and 52g prunes) vs consumed (right, 150g porridge, 11g brown 
sugar, 0g white toast, 0g marmalade, 48g prunes ) by a participant.  
     
 
Example 2: Lunch meal provided (left, 132g chicken cacciatore, 64g mixed 
vegetables, 71g courgette, and 66g mashed potato) vs consumed (right, 125g chicken 
cacciatore, 58g mixed vegetables, 71g courgette, and 60g mashed potato) by a 
participant. 
     
